U.S. patent application number 16/802959 was filed with the patent office on 2021-01-21 for pyrimidinyl tyrosine kinase inhibitors.
The applicant listed for this patent is Biogen MA Inc., Sunesis Pharmaceuticals, Inc.. Invention is credited to Xiongwei CAI, Timothy R. CHAN, Patrick CONLON, Brian T. HOPKINS, Michael HUMORA, Tracy J. JENKINS, Ross A. MILLER, Xianglin SHI, Andrew THOMPSON.
Application Number | 20210017155 16/802959 |
Document ID | / |
Family ID | 1000005131610 |
Filed Date | 2021-01-21 |
View All Diagrams
United States Patent
Application |
20210017155 |
Kind Code |
A1 |
HOPKINS; Brian T. ; et
al. |
January 21, 2021 |
PYRIMIDINYL TYROSINE KINASE INHIBITORS
Abstract
The present invention provides compounds and compositions
thereof which are useful as inhibitors of Bruton's tyrosine kinase
and which exhibit desirable characteristics for the same.
Inventors: |
HOPKINS; Brian T.; (Newton,
MA) ; CHAN; Timothy R.; (Newton, MA) ;
JENKINS; Tracy J.; (Watertown, MA) ; CONLON;
Patrick; (Wakefield, MA) ; CAI; Xiongwei;
(Arlington, MA) ; HUMORA; Michael; (Cranbury,
NJ) ; SHI; Xianglin; (Cambridge, MA) ; MILLER;
Ross A.; (South Plainfield, NJ) ; THOMPSON;
Andrew; (Portola Valley, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Sunesis Pharmaceuticals, Inc.
Biogen MA Inc. |
South San Francisco
Cambridge |
CA
MA |
US
US |
|
|
Family ID: |
1000005131610 |
Appl. No.: |
16/802959 |
Filed: |
February 27, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15911546 |
Mar 5, 2018 |
10618887 |
|
|
16802959 |
|
|
|
|
15196389 |
Jun 29, 2016 |
9944622 |
|
|
15911546 |
|
|
|
|
14406315 |
Dec 8, 2014 |
9394277 |
|
|
PCT/US2013/044800 |
Jun 7, 2013 |
|
|
|
15196389 |
|
|
|
|
61657360 |
Jun 8, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 401/14
20130101 |
International
Class: |
C07D 401/14 20060101
C07D401/14 |
Claims
1. A pharmaceutical salt of formula I: ##STR00090## wherein: each
R.sup.1 is independently hydrogen, an optionally substituted
C.sub.1-6 aliphatic group, an optionally substituted 3-7 membered
monocyclic heterocyclic group, or an optionally substituted
heterocyclylalkyl group having 3-7 carbon atoms and 1-3 heteroatoms
independently selected from nitrogen, oxygen, and sulfur; or two
R.sup.1 groups are taken together with their intervening atoms to
form an optionally substituted 3-7 membered saturated or partially
unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms
independently selected from nitrogen, oxygen, and sulfur; wherein
optionally substituted groups may be substituted with halogen,
--NO.sub.2, --CN, --OR, --SR, --N(R).sub.2, --C(O)R, --CO.sub.2R,
--N(R)C(O)OR, --C(O)N(R).sub.2, --OC(O)R, --N(R)C(O)R, --S(O)R,
--S(O).sub.2R, or --S(O).sub.2N(R).sub.2; each R is independently
hydrogen or C.sub.1-6 aliphatic; or two R groups attached to the
same nitrogen are taken together with their intervening atoms to
form an optionally substituted 3-7 membered saturated or partially
unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms, in
which any second heteroatom is independently selected from
nitrogen, oxygen, and sulfur; Ring A is ##STR00091## R.sup.2 is
--Cl or --F; and R.sup.3 is --CF.sub.3, --OCF.sub.3, or --F.
2. The pharmaceutical salt of claim 1, wherein the compound is of
formula II-a: ##STR00092##
3. The pharmaceutical salt of claim 1, wherein the compound is of
formula II-b: ##STR00093##
4. The pharmaceutical salt of claim 1, wherein the compound is of
formula III: ##STR00094##
5. The pharmaceutical salt of claim 1, wherein the compound is
formula IV: ##STR00095##
6. The pharmaceutical salt of claim 5, wherein R.sup.3 is
--CF.sub.3 or --F.
7. (canceled)
8. The pharmaceutical salt of claim 5, wherein both R.sup.1 are
hydrogen.
9. The pharmaceutical salt of claim 5, wherein one R.sup.1 is
hydrogen and the other R is an optionally substituted C.sub.1-6
aliphatic.
10. The pharmaceutical salt of claim 9, wherein one R.sup.1 is
hydrogen and the other R.sup.1 is methyl.
11. The pharmaceutical salt of claim 5, wherein both R.sup.1 are
optionally substituted C.sub.1-6 aliphatic groups.
12. The pharmaceutical salt of claim 1, wherein one R.sup.1 is
hydrogen and the other an is optionally substituted C.sub.1-6
aliphatic.
13. The pharmaceutical salt of claim 1, wherein both R.sup.1 are
optionally substituted C.sub.1-6 aliphatic groups.
14. The pharmaceutical salt of claim 1, wherein both R.sup.1 are
hydrogen.
15.-19. (canceled)
20. A pharmaceutical salt selected from the group consisting of:
##STR00096## ##STR00097##
21. A method of decreasing the enzymatic activity of Bruton's
tyrosine kinase comprising contacting Bruton's tyrosine kinase with
an effective amount of a pharmaceutical salt of claim 1 or a
composition thereof.
22. A method of treating a disorder responsive to inhibition of
Bruton's tyrosine kinase comprising administering to a subject an
effective amount of a pharmaceutical salt of claim 1 or a
composition thereof.
23. A method of treating a disorder selected from the group
consisting of autoimmune disorders, inflammatory disorders, and
cancers comprising administering to a subject an effective amount
of a pharmaceutical salt of claim 1 or a composition thereof.
24. The method of claim 23, wherein the disorder is rheumatoid
arthritis, systemic lupus erythematosus, or atopic dermatitis.
25.-26. (canceled)
27. The method of claim 23, wherein the disorder is leukemia or
lymphoma.
28. A pharmaceutical composition comprising a pharmaceutical salt
of claim 1 and one or more pharmaceutically acceptable excipients.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S.
application Ser. No. 15/911,546, filed on Mar. 5, 2018 (now
allowed), which is a continuation of U.S. application Ser. No.
15/196,389, filed on Jun. 29, 2016 (now U.S. Pat. No. 9,944,622),
which is a continuation of U.S. application Ser. No. 14/406,315,
filed Dec. 8, 2014 (now U.S. Pat. No. 9,394,277), which is a U.S.
National Phase application, filed under 35 U.S.C. .sctn. 371, of
International Application No. PCT/US2013/044800, filed Jun. 7,
2013, which claims priority to U.S. provisional application Ser.
No. 61/657,360, filed Jun. 8, 2012, the entire contents of each of
which are hereby incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] The Tec kinases are non-receptor tyrosine kinases including:
Tec (tyrosine kinase expressed in hepatocellular carcinoma), Btk
(Bruton's tyrosine kinase), Itk (interleukin-2 (IL-2)-inducible
T-cell kinase; also known as Emt or Tsk), Rlk (resting lymphocyte
kinase; also known as Txk), Lck (lymphocyte-specific protein
tyrosine kinase), and Bmx (bone-marrow tyrosine kinase gene on
chromosome X; also known as Etk)). These kinases are primarily
expressed in haematopoietic cells, although expression of Bmx and
Tec has been detected in endothelial and liver cells. Tec kinases
(Itk, Rlk and Tec) are expressed in T cells and are all activated
downstream of the T-cell receptor (TCR). Btk is a downstream
mediator of B cell receptor (BCR) signaling which is involved in
regulating B cell activation, proliferation, and differentiation.
More specifically, Btk contains a PH domain that binds
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binding
induces Btk to phosphorylate phospholipase C (PLC), which in turn
hydrolyzes PIP2 to produce two secondary messengers, inositol
triphosphate (IP3) and diacylglycerol (DAG), which activate protein
kinase PKC, which then induces additional B-cell signaling.
Mutations that disable Btk enzymatic activity result in XLA
syndrome (X-linked agammaglobulinemia), a primary immunodeficiency.
Given the critical roles which Tec kinases play in both B-cell and
T-cell signaling, Tec kinases are targets of interest for
autoimmune disorders.
[0003] Consequently, there is a great need in the art for effective
inhibitors for Tec kinases such as Btk. The present invention
fulfills these and other needs.
SUMMARY OF THE INVENTION
[0004] In certain embodiments, the present invention provides a
compound of formula I
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1 and
Ring A are as defined and described herein. Such compounds are
inhibitors of the Tec kinase family, including Btk. Accordingly,
provided compounds can be used in a variety of methods including in
vitro screening and activity assays as well as in vivo
pre-clinical, clinical, and therapeutic settings, as described in
detail herein.
[0005] In certain embodiments, the present invention provides
pharmaceutical formulations comprising provided compounds.
[0006] In certain embodiments, the present invention provides a
method of decreasing enzymatic activity of Btk. In some
embodiments, such methods include contacting Btk with an effective
amount of a Btk inhibitor.
[0007] In certain embodiments, the present invention provides a
method of treating a disorder responsive to Btk inhibition in a
subject in need thereof. Such disorders and methods are described
in detail herein.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
[0008] In certain embodiments, the present invention provides a
compound of formula I:
##STR00002##
or a pharmaceutically acceptable salt thereof; wherein: [0009] each
R.sup.1 is independently hydrogen, an optionally substituted
C.sub.1-6 aliphatic group, an optionally substituted 3-7 membered
monocyclic heterocyclic group, or an optionally substituted
heterocyclylalkyl group having 3-7 carbon atoms and 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; [0010] or
two R.sup.1 groups are taken together with their intervening atoms
to form an optionally substituted 3-7 membered saturated or
partially unsaturated monocyclic heterocyclic ring having 1-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur; [0011] wherein optionally substituted groups may be
substituted with halogen, --NO.sub.2, --CN, --OR, --SR,
--N(R).sub.2, --C(O)R, --CO.sub.2R, --N(R)C(O)OR, --C(O)N(R).sub.2,
--OC(O)R, --N(R)C(O)R, --S(O)R, --S(O).sub.2R, or
--S(O).sub.2N(R).sub.2; [0012] each R is independently hydrogen or
C.sub.1-6 aliphatic; [0013] or two R groups attached to the same
nitrogen are taken together with their intervening atoms to form an
optionally substituted 3-7 membered saturated or partially
unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms, in
which any second heteroatom is independently selected from
nitrogen, oxygen, or sulfur; [0014] Ring A is
[0014] ##STR00003## [0015] R.sup.2 is --Cl or --F; and [0016]
R.sup.3 is --CF.sub.3, --OCF.sub.3, or --F.
Definitions
[0017] Compounds of this invention include those described
generally above, and are further illustrated by the classes,
subclasses, and species disclosed herein. As used herein, the
following definitions shall apply unless otherwise indicated. For
purposes of this invention, the chemical elements are identified in
accordance with the Periodic Table of the Elements, CAS version,
Handbook of Chemistry and Physics, 75.sup.th Ed. Additionally,
general principles of organic chemistry are described in "Organic
Chemistry", Thomas Sorrell, University Science Books, Sausalito:
1999, and "March's Advanced Organic Chemistry", 5.sup.th Ed., Ed.:
Smith, M. B. and March, J., John Wiley & Sons, New York: 2001,
the entire contents of which are hereby incorporated by
reference.
[0018] The abbreviations used herein have their conventional
meaning within the chemical and biological arts. The chemical
structures and formulae set forth herein are constructed according
to the standard rules of chemical valency known in the chemical
arts.
[0019] The term "aliphatic" or "aliphatic group", as used herein,
means a straight-chain (i.e., unbranched) or branched, substituted
or unsubstituted hydrocarbon chain that is completely saturated or
that contains one or more units of unsaturation, or a monocyclic
hydrocarbon or bicyclic hydrocarbon that is completely saturated or
that contains one or more units of unsaturation, but which is not
aromatic (also referred to herein as "carbocycle," "cycloaliphatic"
or "cycloalkyl"), that has a single point of attachment to the rest
of the molecule. Unless otherwise specified, aliphatic groups
contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic
groups contain 1-5 aliphatic carbon atoms. In some embodiments,
aliphatic groups contain 1-4 aliphatic carbon atoms. In some
embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms,
and in yet other embodiments, aliphatic groups contain 1-2
aliphatic carbon atoms. Suitable aliphatic groups include, but are
not limited to, linear or branched, substituted or unsubstituted
alkyl, alkenyl, alkynyl groups and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0020] As used herein, the term "cycloaliphatic" (or "carbocycle"
or "cycloalkyl") refers to a monocyclic C.sub.3-C.sub.6 hydrocarbon
that is completely saturated or that contains one or more units of
unsaturation, but which is not aromatic, that has a single point of
attachment to the rest of the molecule.
[0021] As used herein, the terms "heterocycle," "heterocyclyl," and
"heterocyclic ring" are used interchangeably and refer to a stable
3- to 7-membered monocyclic heterocyclic moiety that is either
saturated or partially unsaturated, and having, in addition to
carbon atoms, one or more, preferably one to four, heteroatoms, as
defined above. When used in reference to a ring atom of a
heterocycle, the term "nitrogen" includes a substituted nitrogen.
As an example, in a saturated or partially unsaturated ring having
0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the
nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl), or .sup.+NR (as in N-substituted pyrrolidinyl). The
term "heterocyclylalkyl" refers to an alkyl group substituted by a
heterocyclyl, wherein the alkyl and heterocyclyl portions
independently are optionally substituted.
[0022] A heterocyclic ring can be attached to its pendant group at
any heteroatom or carbon atom that results in a stable structure
and any of the ring atoms can be optionally substituted. Examples
of such saturated or partially unsaturated heterocyclic radicals
include, without limitation, tetrahydrofuranyl,
tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl,
oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
[0023] As used herein, the term "partially unsaturated" refers to a
ring moiety that includes at least one double or triple bond. The
term "partially unsaturated" is intended to encompass rings having
multiple sites of unsaturation, but is not intended to include aryl
or heteroaryl moieties, as herein defined.
[0024] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or silicon (including, any oxidized form of
nitrogen, sulfur, phosphorus, or silicon; the quaternized form of
any basic nitrogen or; a substitutable nitrogen of a heterocyclic
ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl) or NR.sup.+ (as in N-substituted pyrrolidinyl)).
[0025] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. Pharmaceutically acceptable salts are well
known in the art. For example, S. M. Berge et al., describe
pharmaceutically acceptable salts in detail in J. Pharmaceutical
Sciences, 1977, 66, 1-19, incorporated herein by reference.
[0026] In certain embodiments, the neutral forms of the compounds
are regenerated by contacting the salt with a base or acid and
isolating the parent compound in the conventional manner. In some
embodiments, the parent form of the compound differs from the
various salt forms in certain physical properties, such as
solubility in polar solvents.
[0027] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, Z
and E double bond isomers, and Z and E conformational isomers.
Therefore, single stereochemical isomers as well as enantiomeric,
diastereomeric, and geometric (or conformational) mixtures of the
present compounds are within the scope of the invention. Unless
otherwise stated, all tautomeric forms of the compounds of the
invention are within the scope of the invention. Additionally,
unless otherwise stated, structures depicted herein are also meant
to include compounds that differ only in the presence of one or
more isotopically enriched atoms. For example, compounds having the
present structures including the replacement of hydrogen by
deuterium or tritium, or the replacement of a carbon by a .sup.13C-
or .sup.14C-enriched carbon are within the scope of this invention.
Such compounds are useful, for example, as analytical tools, as
probes in biological assays, or as therapeutic agents in accordance
with the present invention.
Compounds
[0028] As described above, in certain embodiments the present
invention provides a compound of formula I:
##STR00004##
of a pharmaceutically acceptable salt thereof, wherein R.sup.1 and
Ring A are as defined and described herein.
[0029] Compounds of formula I have unexpectedly been found to
exhibit advantageous properties over known inhibitors of Btk. In
certain embodiments, compounds of formula I have increased potency.
Without wishing to be bound by any particular theory, it is
believed that compounds disclosed herein possess improved potency
as Btk inhibitors, an improved off-target profile as measured by
hERG inhibition or PXR induction assays, or a combination thereof.
Experimental data showing such advantageous properties is provided
in the ensuing Examples.
[0030] In some embodiments, both R.sup.1 are hydrogen. In some
embodiments, each R.sup.1 is independently C.sub.1-6 aliphatic. In
some embodiments, each R.sup.1 is independently C.sub.1-5
aliphatic. In some embodiments, each R.sup.1 is independently
C.sub.1-4 aliphatic. In some embodiments, each R.sup.1 is
independently C.sub.1-3 aliphatic. In some embodiments, each
R.sup.1 is independently C.sub.1-2 aliphatic. In some embodiments,
both R.sup.1 are methyl.
[0031] In some embodiments, each R.sup.1 is independently hydrogen
or C.sub.1-6 aliphatic. In some embodiments, each R.sup.1 is
independently hydrogen or C.sub.1-5 aliphatic. In some embodiments,
each R.sup.1 is independently hydrogen or C.sub.1-4 aliphatic. In
some embodiments, each R.sup.1 is independently hydrogen or
C.sub.1-3 aliphatic. In some embodiments, each R.sup.1 is
independently hydrogen or C.sub.1-2 aliphatic. In some embodiments,
each R.sup.1 is independently hydrogen or methyl.
[0032] In some embodiments, one R.sup.1 is hydrogen or and the
other R.sup.1 is C.sub.1-6 aliphatic. In some embodiments, one
R.sup.1 is hydrogen and the other R.sup.1 is methyl. In some
embodiments, one R.sup.1 is hydrogen and the other R.sup.1 is
ethyl. In some embodiments, one R.sup.1 is hydrogen and the other
R.sup.1 is C.sub.1-6 (cycloalkyl)alkyl. In some embodiments, one
R.sup.1 is hydrogen and the other R.sup.1 is C.sub.1-6
(cycloalkyl).
[0033] In some embodiments, one R.sup.1 is hydrogen and the other
R.sup.1 is C.sub.1-6 aliphatic optionally substituted with --OR,
wherein R is hydrogen or C.sub.1-6 aliphatic.
[0034] In some embodiments, one R.sup.1 is hydrogen and the other
R.sup.1 is a heterocyclylalkyl group having 3-7 carbon atoms and
1-3 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In some embodiments, one R.sup.1 is hydrogen and the other
R.sup.1 is an optionally substituted 3-7 membered monocyclic
heterocycle.
[0035] In some embodiments, two R.sup.1 groups are taken together
with their intervening atoms to form an optionally substituted 3-5
membered saturated or partially unsaturated monocyclic heterocyclic
ring having 1-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur. In some embodiments, two R.sup.1 groups are
taken together with their intervening atoms to form an optionally
substituted piperazine ring.
[0036] As described above, Ring A is
##STR00005##
In certain embodiments, R.sup.2 is --Cl. In other embodiments,
R.sup.2 is --F. In some embodiments, R.sup.3 is --CF.sub.3. In some
embodiments, R.sup.3 is --OCF.sub.3. In some embodiments, R.sup.3
is --F.
[0037] In certain embodiments, Ring A is selected from the group
consisting of:
##STR00006##
[0038] In some embodiments, in compounds described herein there is
a trans stereochemical relationship between the piperidine
substituent bearing the carboxamide group and the piperidine
substituent bearing the lactam group.
[0039] In some embodiments, the present invention provides a
compound of formula II-a:
##STR00007##
or a pharmaceutically acceptable salt thereof, wherein each of
R.sup.1, R.sup.2, and R.sup.3 is as defined above and described in
classes and subclasses herein.
[0040] In some embodiments, the present invention provides a
compound of formula II-b:
##STR00008##
or a pharmaceutically acceptable salt thereof, wherein each of
R.sup.1, R.sup.2, and R.sup.3 is as defined above and described in
classes and subclasses herein.
[0041] In some embodiments, the present invention provides a
compound of formula III:
##STR00009##
or a pharmaceutically acceptable salt thereof, wherein each of
R.sup.2 and R.sup.3 is as defined above and described in classes
and subclasses herein.
[0042] In some embodiments, the present invention provides a
compound of formula IV:
##STR00010##
or a pharmaceutically acceptable salt thereof, wherein each of
R.sup.1 and R.sup.3 is as defined above and described in classes
and subclasses herein. In some embodiments, both R.sup.1 are
hydrogen. In some embodiments, one R.sup.1 is hydrogen and the
other R.sup.1 is methyl.
[0043] In some embodiments, a provided compound is a compound
depicted in Table 1, below, or a pharmaceutically acceptable salt
thereof.
Table 1--Selected compounds of formula I.
##STR00011## ##STR00012##
[0044] Compounds of the invention are synthesized by an appropriate
combination of generally well known synthetic methods. Techniques
useful in synthesizing the compounds of the invention are both
readily apparent and accessible to those of skill in the relevant
art. The discussion below is offered to illustrate certain of the
diverse methods available for use in assembling the compounds of
the invention. However, the discussion is not intended to define
the scope of reactions or reaction sequences that are useful in
preparing the compounds of the present invention.
[0045] Compounds of formula I may be generally prepared according
to Scheme 1.
##STR00013## ##STR00014##
[0046] Compounds of formula I may also be generally prepared
according to Schemes 2, 3, 3a, 4, 4a, 5, or 5a.
##STR00015## ##STR00016##
##STR00017## ##STR00018##
##STR00019## ##STR00020##
##STR00021## ##STR00022##
##STR00023## ##STR00024##
##STR00025## ##STR00026##
##STR00027## ##STR00028##
[0047] The PG, PG.sub.1, PG.sub.2, and PG.sub.3 groups of compounds
in Schemes 1 through 5a are each independently a suitable
protecting group. Such ester and amine protecting groups are known
in the art and are described in detail in Protecting Groups in
Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd
edition, John Wiley & Sons, 1999, the entirety of which is
incorporated herein by reference. In some embodiments, a protecting
group is a Boc group.
[0048] In certain embodiments, each of the synthetic steps in
Schemes 1 through 5a may be performed sequentially with isolation
of each intermediate performed after each step. Alternatively, each
of the steps as depicted in Schemes 1, 2, 3, and 4 above, may be
performed in a manner whereby no isolation of one or more
intermediates is performed.
[0049] In certain embodiments, all the steps of the aforementioned
synthesis may be performed to prepare the desired final product. In
other embodiments, two, three, four, five, or more sequential steps
may be performed to prepare an intermediate or the desired final
product.
Uses, Formulation and Administration
[0050] In certain embodiments, compounds of the present invention
are for use in medicine. In some embodiments, the present invention
provides method of decreasing enzymatic activity of a kinase in the
Tec kinase family (e.g., Tec, Btk, Itk, Txk, Lck, and Bmx). In some
embodiments, such methods include contacting a kinase of the Tec
kinase family with an effective amount of a Tec kinase family
inhibitor. Therefore, the present invention further provides
methods of inhibiting Tec kinase family enzymatic activity by
contacting a Tec kinase family member with a Tec kinase family
inhibitor of the present invention. As used herein, the term "Tec
kinase family member" refers to any non-receptor tyrosine kinase in
the Tec kinase family. In some embodiments, Tec kinase family
members are Tec, Btk, Itk, Txk, Lck, and Bmx.
[0051] In some embodiments, the present invention provides methods
of decreasing Btk enzymatic activity. In some embodiments, such
methods include contacting a Btk with an effective amount of a Btk
inhibitor. Therefore, the present invention further provides
methods of inhibiting Btk enzymatic activity by contacting a Btk
with a Btk inhibitor of the present invention.
[0052] Btk enzymatic activity, as used herein, refers to Btk kinase
enzymatic activity. For example, where Btk enzymatic activity is
decreased, PIP3 binding and/or phosphorylation of PLC.gamma. is
decreased. In some embodiments, the half maximal inhibitory
concentration (IC.sub.50) of the Btk inhibitor against Btk is less
than 1 M. In some embodiments, the IC.sub.50 of the Btk inhibitor
against Btk is less than 500 nM. In some embodiments, the IC.sub.50
of the Btk inhibitor against Btk is less than 100 nM. In some
embodiments, the IC.sub.50 of the Btk inhibitor against Btk is less
than 10 nM. In some embodiments, the IC.sub.50 of the Btk inhibitor
against Btk is less than 1 nM. In some embodiments, the IC.sub.50
of the Btk inhibitor against Btk is from 0.1 nM to 10 M. In some
embodiments, the IC.sub.50 of the Btk inhibitor against Btk is from
0.1 nM to 1 M. In some embodiments, the IC.sub.50 of the Btk
inhibitor against Btk is from 0.1 nM to 100 nM. In some
embodiments, the IC.sub.50 of the Btk inhibitor against Btk is from
0.1 nM to 10 nM.
[0053] In some embodiments, inhibitors of such Tec kinases are
useful for the treatment of diseases and disorders that may be
alleviated by inhibiting (i.e., decreasing) enzymatic activity of
one or more Tec kinases. The compounds of the invention are
effective inhibitors of Tec family kinases and would thus be useful
in treating diseases associated with the activity of one or more of
the Tec family kinases. The term "diseases" means diseases,
syndromes, or disease symptoms. Thus, the present invention
provides methods of treating autoimmune disorders, inflammatory
disorders, and cancers in a subject in need thereof. Such methods
include administering to the subject a therapeutically effective
amount of an inhibitor of Tec, Btk, Itk, Txk, Lck, and/or Bmx
kinase.
[0054] The term "autoimmune disorders" includes diseases or
disorders involving inappropriate immune response against native
antigens, such as acute disseminated encephalomyelitis (ADEM),
Addison's disease, alopecia areata, antiphospholipid antibody
syndrome (APS), hemolytic anemia, autoimmune hepatitis, bullous
pemphigoid (BP), Coeliac disease, dermatomyositis, diabetes
mellitus type 1, Good Pasture's syndrome, Graves' disease,
Guillain-Barre syndrome (GBS), Hashimoto's disease, idiopathic
thrombocytopenic purpura, lupus or systemic lupus erythematosus
(SLE), mixed connective tissue disease, multiple sclerosis,
myasthenia gravis, pemphigus vulgaris, hemophilia with inhibitors,
pernicious anaemia, polymyositis, primary biliary cirrhosis,
Sjogren's syndrome, temporal arteritis, and Wegener's
granulomatosis. The term "inflammatory disorders" includes diseases
or disorders involving acute or chronic inflammation such as
allergies, asthma (e.g., allergic asthma), atopic dermatitis,
prostatitis, glomerulonephritis, pelvic inflammatory disease (PID),
inflammatory bowel disease (IBD, e.g., Crohn's disease, ulcerative
colitis), reperfusion injury, rheumatoid arthritis, transplant
rejection (including transplant patients with a positive
cross-match) and vasculitis. In certain embodiments, the present
invention provides methods of treating disease, disorders, or
conditions that approved for treatment with rituximab (a monoclonal
antibody against CD20), including non-Hodgkin's lymphoma (NHL),
chronic lymphocytic leukemia (CLL), RA, Wegener's granulomatosis
(WG), and microscopic polyangiitis (MPA). In some embodiments, the
present invention provides a method of treating rheumatoid
arthritis (RA), SLE, or atopic dermatitis using compounds disclosed
herein.
[0055] The term "cancer" includes diseases or disorders involving
abnormal cell growth and/or proliferation, such as glioma, thyroid
carcinoma, breast carcinoma, lung cancer (e.g. small-cell lung
carcinoma, non-small-cell lung carcinoma), gastric carcinoma,
gastrointestinal stromal tumors, pancreatic carcinoma, bile duct
carcinoma, ovarian carcinoma, endometrial carcinoma, prostate
carcinoma, renal cell carcinoma, lymphoma (e.g., anaplastic
large-cell lymphoma), leukemia (e.g. acute myeloid leukemia, T-cell
leukemia, chronic lymphocytic leukemia), multiple myeloma,
malignant mesothelioma, malignant melanoma, and colon cancer (e.g.
microsatellite instability-high colorectal cancer). In some
embodiments, the present invention provides a method of treating
leukemia or lymphoma.
[0056] The term "subject," as used herein, refers to a mammal to
whom a pharmaceutical composition is administered. Exemplary
subjects include humans, as well as veterinary and laboratory
animals such as horses, pigs, cattle, dogs, cats, rabbits, rats,
mice, and aquatic mammals.
Selected Indications and B Cell Inhibition
[0057] As described above, provided compounds are useful for the
treatment of disease, including RA and SLE. As described in more
detail below, these diseases are affiliated with B cells. Thus, the
present disclosure encompasses the recognition that provided
compounds are useful as therapeutics for these and other
indications.
[0058] Dysregulation of the immune system is central to the
pathogenesis (Panayi G S, et al. Rheum Dis Clin North Am 2001;
27:317-334) of RA. While most of the infiltrating leukocytes in the
synovium are T lymphocytes (primarily activated CD4+ T cells) and
cells of monocyte/macrophage origin (which release pro-inflammatory
cytokines such as IL-1, TNF-alpha and IL-6 and proteolytic enzymes
including collagenases and metalloproteinases), B-cells and plasma
cells are also found in the synovial fluid (Zhang Z, Bridges S L.
Rheum Dis Clin North Am 2001; 27:335-353). A clear role for B cells
and their associated effector functions in RA have been
demonstrated by the efficacy of rituximab, a selective B cell
depleting therapeutic, which is approved for treatment of RA (Cohen
S B, et al.; REFLEX Trial Group. Arthritis Rheum. 2006 September;
54(9):2793-806).
[0059] Although the etiology of SLE is not fully understood,
pathogenic autoantibodies and deposition of immune complexes are
felt to be critical to the development of widespread tissue damage
(Klippel J H, et al. Primer on the rheumatic diseases. Atlanta:
Arthritis Foundation; 2001). Autoantibody and immune-complex
mediated activation can be studied by measuring inhibition of
macrophage activation by macrophages stimulated through Fc
receptors (see exemplification--Fc.gamma.R activation of primary
human macrophages). Loss of tolerance to self-antigens ultimately
lead to the stimulation of B cells to produce auto-antibodies often
directed against nuclear or cytoplasmic components. Antibodies
against nuclear components (anti-nuclear antibodies [ANA]) target
nuclear antigens including DNA (typically double-stranded DNA
[dsDNA]), RNA, histones and small nuclear ribonucleoproteins. These
antibodies combine with self-antigens forming immune complexes
which deposit in tissues, incite inflammatory reactions and lead to
tissue injury. In addition to their roles in pathogenic
autoantibody production, B cells also function as
antigen-presenting cells (APCs) to T-cells thus playing a role in
the initiation of an antigen-specific response. Given the central
role of the humoral arm of the immune system in the pathogenesis of
SLE, B cells or the B-cell pathway represent desirable therapeutic
targets. Belimumab, a monoclonal antibody recently approved for
SLE, blocks the binding BAFF to its receptors that are expressed B
cells. These receptors serve to activate and potentiate the
survival of B cells consistent with a reduction of circulating B
cells observed following treatment with belimumab. See also Chan O
T, et al. Immunol Rev. 1999b; 169:107-121; Navarra S V, et al.
Lancet. 2011 Feb. 26; 377(9767):721-31; Furie R, et al. Arthritis
Rheum. 2011 December; 63(12):3918-30. The role of B cells and
myeloid lineage cells in autoimmune diseases such as SLE is further
supported by a recent publication which describes efficacy in a
preclinical SLE animal model when mice are treated with a small
molecule irreversible Btk inhibitor (Honigberg, L. A. PNAS. 2010;
107: 13075).
Combinations
[0060] In certain embodiments, a compound of the present invention
is administered in combination with another agent. In some
embodiments, a compound of the present invention is useful for
treating RA and is administered in combination with a
disease-modifying antirheumatic drugs (DMARD), including without
limitation: methotrexate, abatacept, azathioprine, certolizumab,
chloroquine and hydroxychloroquine, cyclosporin, D-penicillamine,
adalimumab, etanercept, golimumab, gold salts (including auranofin
and sodium aurothiomalate), infliximab, leflunomide, minocycline,
rituximab, sulfasalazine, tocilizumab, or combinations thereof. In
some embodiments, a compound of the present invention is
administered in combination with a NSAID or corticosteroid. In some
embodiments, a compound of the present invention is useful for
treating SLE and is administered in combination with an agent for
the treatment of SLE, including without limitation:
corticosteroids, antimalarials, belimumab, mycophenolate mofetil
(MMF) or mycophenolate sodium, azathioprine, or combinations
thereof. In some embodiments, a compound of the present invention
is useful for treating atopic dermatitis and is administered in
combination with a topical agent for the treatment of atopic
dermatitis, including without limitation: topical steroids,
tacrolimus, methotrexate, mometasone furoate (MMF), azathioprine,
retinoids, or combinations thereof.
Assays
[0061] To develop useful Tec kinase family inhibitors, candidate
inhibitors capable of decreasing Tec kinase family enzymatic
activity may be identified in vitro. The activity of the inhibitor
compounds can be assayed utilizing methods known in the art and/or
those methods presented herein.
[0062] Compounds that decrease Tec kinase family members' enzymatic
activity may be identified and tested using a biologically active
Tec kinase family member, either recombinant or naturally
occurring. Tec kinases can be found in native cells, isolated in
vitro, or co-expressed or expressed in a cell. Measuring the
reduction in the Tec kinase family member enzymatic activity in the
presence of an inhibitor relative to the activity in the absence of
the inhibitor may be performed using a variety of methods known in
the art, such as the POLYGAT-LS assays described below in the
Examples. Other methods for assaying the activity of Btk and other
Tec kinases are known in the art. The selection of appropriate
assay methods is well within the capabilities of those of skill in
the art.
[0063] Once compounds are identified that are capable of reducing
Tec kinase family members' enzymatic activity, the compounds may be
further tested for their ability to selectively inhibit a Tec
kinase family member relative to other enzymes.
[0064] Compounds may be further tested in cell models or animal
models for their ability to cause a detectable changes in phenotype
related to a Tec kinase family member activity. In addition to cell
cultures, animal models may be used to test Tec kinase family
member inhibitors for their ability to treat autoimmune disorders,
inflammatory disorders, or cancer in an animal model.
Pharmaceutical Compositions
[0065] In another aspect, the present invention provides
pharmaceutical compositions comprising a compound of formula I or a
compound of formula I in combination with a pharmaceutically
acceptable excipient (e.g., carrier).
[0066] The pharmaceutical compositions include optical isomers,
diastereomers, or pharmaceutically acceptable salts of the
inhibitors disclosed herein. The compound of formula I included in
the pharmaceutical composition may be covalently attached to a
carrier moiety, as described above. Alternatively, the compound of
formula I included in the pharmaceutical composition is not
covalently linked to a carrier moiety.
[0067] A "pharmaceutically acceptable carrier," as used herein
refers to pharmaceutical excipients, for example, pharmaceutically,
physiologically, acceptable organic or inorganic carrier substances
suitable for enteral or parenteral application that do not
deleteriously react with the active agent. Suitable
pharmaceutically acceptable carriers include water, salt solutions
(such as Ringer's solution), alcohols, oils, gelatins, and
carbohydrates such as lactose, amylose or starch, fatty acid
esters, hydroxymethycellulose, and polyvinyl pyrrolidine. Such
preparations can be sterilized and, if desired, mixed with
auxiliary agents such as lubricants, preservatives, stabilizers,
wetting agents, emulsifiers, salts for influencing osmotic
pressure, buffers, coloring, and/or aromatic substances and the
like that do not deleteriously react with the compounds of the
invention.
[0068] The compounds of the invention can be administered alone or
can be co-administered to the subject. Co-administration is meant
to include simultaneous or sequential administration of the
compounds individually or in combination (more than one compound).
The preparations can also be combined, when desired, with other
active substances (e.g. to reduce metabolic degradation).
[0069] Compounds of the present invention can be prepared and
administered in a wide variety of oral, parenteral, and topical
dosage forms. Thus, the compounds of the present invention can be
administered by injection (e.g. intravenously, intramuscularly,
intracutaneously, subcutaneously, intraduodenally, or
intraperitoneally). Also, the compounds described herein can be
administered by inhalation, for example, intranasally.
Additionally, the compounds of the present invention can be
administered transdermally. It is also envisioned that multiple
routes of administration (e.g., intramuscular, oral, transdermal)
can be used to administer the compounds of the invention.
[0070] For preparing pharmaceutical compositions from the compounds
of the present invention, pharmaceutically acceptable carriers can
be either solid or liquid. Solid form preparations include powders,
tablets, pills, capsules, cachets, suppositories, and dispersible
granules. A solid carrier can be one or more substance that may
also act as diluents, flavoring agents, binders, preservatives,
tablet disintegrating agents, or an encapsulating material.
[0071] In powders, the carrier is a finely divided solid in a
mixture with the finely divided active component. In tablets, the
active component is mixed with the carrier having the necessary
binding properties in suitable proportions and compacted in the
shape and size desired.
[0072] The powders and tablets preferably contain from 5% to 70% of
the active compound. Suitable carriers are magnesium carbonate,
magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch,
gelatin, tragacanth, methylcellulose, sodium
carboxymethylcellulose, a low melting wax, cocoa butter, and the
like. The term "preparation" is intended to include the formulation
of the active compound with encapsulating material as a carrier
providing a capsule in which the active component with or without
other carriers, is surrounded by a carrier, which is thus in
association with it. Similarly, cachets and lozenges are included.
Tablets, powders, capsules, pills, cachets, and lozenges can be
used as solid dosage forms suitable for oral administration.
[0073] For preparing suppositories, a low melting wax, such as a
mixture of fatty acid glycerides or cocoa butter, is first melted
and the active component is dispersed homogeneously therein, as by
stirring. The molten homogeneous mixture is then poured into
convenient sized molds, allowed to cool, and thereby to
solidify.
[0074] Liquid form preparations include solutions, suspensions, and
emulsions, for example, water or water/propylene glycol solutions.
For parenteral injection, liquid preparations can be formulated in
solution in aqueous polyethylene glycol solution.
[0075] When parenteral application is needed or desired,
particularly suitable admixtures for the compounds of the invention
are injectable, sterile solutions, preferably oily or aqueous
solutions, as well as suspensions, emulsions, or implants,
including suppositories. In particular, carriers for parenteral
administration include aqueous solutions of dextrose, saline, pure
water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil,
polyoxyethylene-block polymers, and the like. Ampoules are
convenient unit dosages. The compounds of the invention can also be
incorporated into liposomes or administered via transdermal pumps
or patches. Pharmaceutical admixtures suitable for use in the
present invention include those described, for example, in
Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, Pa.) and
WO 96/05309, the teachings of both of which are hereby incorporated
by reference.
[0076] Aqueous solutions suitable for oral use can be prepared by
dissolving the active component in water and adding suitable
colorants, flavors, stabilizers, and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing
the finely divided active component in water with viscous material,
such as natural or synthetic gums, resins, methylcellulose, sodium
carboxymethylcellulose, and other well-known suspending agents.
[0077] Also included are solid form preparations that are intended
to be converted, shortly before use, to liquid form preparations
for oral administration. Such liquid forms include solutions,
suspensions, and emulsions. These preparations may contain, in
addition to the active component, colorants, flavors, stabilizers,
buffers, artificial and natural sweeteners, dispersants,
thickeners, solubilizing agents, and the like.
[0078] The pharmaceutical preparation is preferably in unit dosage
form. In such form the preparation is subdivided into unit doses
containing appropriate quantities of the active component. The unit
dosage form can be a packaged preparation, the package containing
discrete quantities of preparation, such as packeted tablets,
capsules, and powders in vials or ampoules. Also, the unit dosage
form can be a capsule, tablet, cachet, or lozenge itself, or it can
be the appropriate number of any of these in packaged form.
[0079] The quantity of active component in a unit dose preparation
may be varied or adjusted from 0.1 mg to 10000 mg, more typically
1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the
particular application and the potency of the active component. The
composition can, if desired, also contain other compatible
therapeutic agents.
[0080] Some compounds may have limited solubility in water and
therefore may require a surfactant or other appropriate co-solvent
in the composition. Such co-solvents include: Polysorbate 20, 60,
and 80; Pluronic F-68, F-84, and P-103; cyclodextrin; and polyoxyl
35 castor oil. Such co-solvents are typically employed at a level
between about 0.01% and about 2% by weight.
[0081] Viscosity greater than that of simple aqueous solutions may
be desirable to decrease variability in dispensing the
formulations, to decrease physical separation of components of a
suspension or emulsion of formulation, and/or otherwise to improve
the formulation. Such viscosity building agents include, for
example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl
cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose,
carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin
sulfate and salts thereof, hyaluronic acid and salts thereof, and
combinations of the foregoing. Such agents are typically employed
at a level between about 0.01% and about 2% by weight.
[0082] The compositions of the present invention may additionally
include components to provide sustained release and/or comfort.
Such components include high molecular weight, anionic mucomimetic
polymers, gelling polysaccharides, and finely-divided drug carrier
substrates. These components are discussed in greater detail in
U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The
entire contents of these patents are incorporated herein by
reference in their entirety for all purposes.
Effective Dosages
[0083] Pharmaceutical compositions provided by the present
invention include compositions wherein the active ingredient is
contained in a therapeutically effective amount, i.e., in an amount
effective to achieve its intended purpose. The actual amount
effective for a particular application will depend, inter alia, on
the condition being treated. For example, when administered in
methods to treat cancer, such compositions will contain an amount
of active ingredient effective to achieve the desired result (e.g.
decreasing the number of cancer cells in a subject).
[0084] The dosage and frequency (single or multiple doses) of
compound administered can vary depending upon a variety of factors,
including route of administration; size, age, sex, health, body
weight, body mass index, and diet of the recipient; nature and
extent of symptoms of the disease being treated (e.g., the disease
responsive to Btk inhibition); presence of other diseases or other
health-related problems; kind of concurrent treatment; and
complications from any disease or treatment regimen. Other
therapeutic regimens or agents can be used in conjunction with the
methods and compounds of the invention.
[0085] For any compound described herein, the therapeutically
effective amount can be initially determined from cell culture
assays. Target concentrations will be those concentrations of
active compound(s) that are capable of decreasing kinase enzymatic
activity as measured, for example, using the methods described.
[0086] Therapeutically effective amounts for use in humans may be
determined from animal models. For example, a dose for humans can
be formulated to achieve a concentration that has been found to be
effective in animals. The dosage in humans can be adjusted by
monitoring kinase inhibition and adjusting the dosage upwards or
downwards, as described above. In certain embodiments, the
administered dose is in the range of about 10 mg to about 1000 mg
per day, either once, twice, or more than twice daily.
[0087] Dosages may be varied depending upon the requirements of the
patient and the compound being employed. The dose administered to a
patient, in the context of the present invention, should be
sufficient to effect a beneficial therapeutic response in the
patient over time. The size of the dose also will be determined by
the existence, nature, and extent of any adverse side effects.
Generally, treatment is initiated with smaller dosages, which are
less than the optimum dose of the compound. Thereafter, the dosage
is increased by small increments until the optimum effect under
circumstances is reached. In some embodiments, the dosage range is
0.001% to 10% w/v. In some embodiments, the dosage range is 0.1% to
5% w/v.
[0088] Dosage amounts and intervals can be adjusted individually to
provide levels of the administered compound effective for the
particular clinical indication being treated. This will provide a
therapeutic regimen that is commensurate with the severity of the
individual's disease state.
[0089] In order that the invention described herein may be more
fully understood, the following examples are set forth. It should
be understood that these examples are for illustrative purposes
only and are not to be construed as limiting this invention in any
manner.
EXEMPLIFICATION
[0090] As depicted in the Examples below, in certain exemplary
embodiments, compounds are prepared according to the following
general procedures. It will be appreciated that, although the
general methods depict the synthesis of certain compounds of the
present invention, the following general methods, and other methods
known to one of ordinary skill in the art, can be applied to all
compounds and subclasses and species of each of these compounds, as
described herein.
Example 1
Synthetic of (3'R,4'S)-1'-tert-buty 4'-ethyl
2-oxo-[1,3'-bipiperidine]-1',4'-dicarboxylate
##STR00029## ##STR00030##
[0092] Preparation of ethyl 3-oxopiperidine-4-carboxylate
intermediate. Ethyl 1-benzyl-3-oxopiperidine-4-carboxylate 1 (15.0
g, 50.5 mmol, 1.0 equiv) was hydrogenated in the presence of 10%
Pd/C (1.5 g) catalyst under H.sub.2 at atmospheric pressure in MeOH
(250 mL) for 16 h. The catalyst was filtered off and the solvent
was concentrated in vacuo to give ethyl
3-oxopiperidine-4-carboxylate 2 as a light yellow solid (10.2 g,
yield: 98.0%). ESI-MS (M+H).sup.+: 172.1. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta.: 4.23 (q, 2H), 3.75 (s, 2H), 3.37 (s, 2H),
3.20-3.16 (m, 2H), 2.44 (t, 1H), 1.25 (t, 3H).
[0093] Preparation of 1-tert-butyl 4-ethyl
3-oxopiperidine-1,4-dicarboxylate. Ethyl
3-oxopiperidine-4-carboxylate 2 (10.2 g, 60.0 mmol, 1.0 equiv) was
dissolved in dry MeOH (200 mL), and Et.sub.3N (33.1 mL, 240 mmol,
4.0 equiv) was added. The mixture was stirred for 1 h and
Boc.sub.2O (19.5 g, 90.0 mmol, 1.5 equiv) was added and stirred for
16 h. The solvent was concentrated in vacuo and the crude was
purified by column chromatography (silica, petroleum
ether/EtOAc=9:1) to give 1-tert-butyl 4-ethyl
3-oxopiperidine-1,4-dicarboxylate 3 light yellow oil (11.5 g,
yield: 86%). ESI-MS (M+H-56).sup.+: 216.0. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta.: 4.24 (q, 2H), 4.03 (s, 2H), 3.49 (t, 2H), 2.33
(t, 2H), 1.47 (s, 9H), 1.31 (t, 3H).
[0094] Preparation of (S)-1-tert-butyl 4-ethyl
3-((1-phenylethyl)amino)-5,6-dihydro
pyridine-1,4-(2H)-dicarboxylate. In a dry flask equipped with a
Dean-stark trap and reflux condenser, 1-tert-butyl 4-ethyl
3-oxopiperidine-1,4-dicarboxylate 3 (10.0 g, 37.0 mmol, 1.1 equiv)
was dissolved in toluene (100 mL). S-(-)-.alpha.-Methylbenzylamine
(4.9 g, 40.5 mmol, 1.1 equiv) and p-toluenesulfonic acid
monohydrate (0.7 g, 3.7 mmol, 0.1 equiv) were added and the mixture
was heated to reflux for 16 h. The crude reaction mixture was
concentrated in vacuo to give (S)-1-tert-butyl 4-ethyl
3-((1-phenylethyl)amino)-5,6-dihydro pyridine-1,4(2H)-dicarboxylate
4 (12.0 g, Y: 88%) as thick orange oil which was used in next step
without further purification, ESI-MS (M+H).sup.+: 375.2.
[0095] Preparation of 1-tert-butyl 4-ethyl
3-(((S)1-phenylethyl)amino)-5,6-dihydro
pyridine-1,4(2H)-dicarboxylate. 1-tert-Butyl 4-ethyl
3-(((S)-1-phenylethyl)amino)piperidine-1,4-dicarboxylate 4 (11.2 g,
30.0 mmol, 1.0 equiv) was dissolved in a mixture of CH.sub.3CN (60
mL) and acetic acid (60 mL) and cooled to 0.degree. C.
NaBH(OAc).sub.3 (19.0 g, 90.0 mmol, 3.0 equiv) was slowly added and
the reaction mixture was allowed to stir for 2 h at 0.degree. C.
Saturated NaHCO.sub.3 was slowly added to neutralize the solution
to maintain the internal temperature of the flask below 10.degree.
C. The mixture was extracted with EtOAc (50 mL.times.3). The
combined organic layer was dried (Na.sub.2SO.sub.4), filtered,
concentrated in vacuo, and then purified by column chromatography
(silica, petroleum ether/EtOAc=9:1) to give 4-ethyl
3-(((S)1-phenylethyl)amino)-5,6-dihydro
pyridine-1,4(2H)-dicarboxylate 5 (8.2 g, Y: 73%) as light yellow
oil. ESI-MS (M+H).sup.+: 377.2. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta.: 7.31-7.22 (m, 5H), 4.20 (q, 2H), 4.11-3.86 (m, 3H), 3.15
(s, 1H), 3.00-2.90 (m, 2H), 2.64 (d, 2H), 1.87-1.85 (m, 1H), 1.68
(s, 1H), 1.50-1.25 (m, 15H).
[0096] Preparation of trans-1-tert-butyl 4-ethyl
3-(((S)-1-phenylethyl)amino) piperidine-1,4-dicarboxylate. The
1-tert-butyl 4-ethyl
3-(((S)-1-phenylethyl)amino)piperidine-1,4-dicarboxylate 5 (8.0 g,
21.2 mmol, 1.0 equiv) was dissolved in dry EtOH (20 mL) under
N.sub.2. In a separate flame-dried Schlenk flask was placed dry
EtOH (150 mL), and sodium (0.450 g, 63.6 mmol, 3.0 equiv) was added
portion-wise under N.sub.2. The mixture was kept under N.sub.2 and
vented to remove evolved gases until all of the sodium had
dissolved. The clear solution of 1-tert-butyl 4-ethyl
3-(((S)-1-phenylethyl)amino)piperidine-1,4-dicarboxylate was then
transferred to the NaOEt solution, and the mixture was stirred at
80.degree. C. under N.sub.2 for 16 h. The solvent was removed under
in vacuo, and brine (150 mL) was added and the mixture was brought
to pH=10 with 1 N NaOH and extracted with EtOAc (100 mL.times.3).
The combined organic layers were dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The residue was purified by column
chromatography (silica, petroleum ether/EtOAc=5:1) to give
(trans)-1-tert-butyl 4-ethyl 3-(((S)-1-phenylethyl)
amino)piperidine-1,4-dicarboxylate 6 as a slight yellow solid (3.7
g, yield: 46%). ESI-MS (M+H).sup.+: 377.2.
[0097] Preparation of trans-1-tert-butyl 4-ethyl
3-aminopiperidine-1,4-dicarboxylate. Trans-1-tert-butyl 4-ethyl
3-(((S)-1-phenylethyl)amino)piperidine-1,4-dicarboxylate 6 (3.7 g,
8.3 mmol, 1.0 equiv) was hydrogenated in the presence of 10% Pd/C
(0.37 g) catalyst under H.sub.2 at 30 atmospheric pressure in MeOH
(100 mL) at 50.degree. C. for 8 h. The catalyst was filtered off
and the solvent was removed in vacuo to give (trans)-1-tert-butyl
4-ethyl 3-aminopiperidine-1,4-dicarboxylate 7 as light yellow oil
(2.5 g, yield: 92%). ESI-MS (M+H).sup.+: 273.1. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta.: 4.18 (q, 2H), 3.97-3.94 (m, 2H), 3.37 (s,
1H), 3.07-3.02 (m, 1H), 2.89-2.85 (m, 1H), 2.60-2.55 (m, 1H),
2.01-1.91 (m, 1H), 1.70-1.54 (m, 3H), 1.46 (s, 9H), 1.28 (t,
3H).
[0098] Synthesis of trans-1-tert-butyl 4-ethyl
3-(5-bromopentanamido)piperidine-1,4-dicarboxylate. To a solution
of trans-1-tert-butyl 4-ethyl 3-aminopiperidine-1,4-dicarboxylate 7
(2.5 g, 9.2 mmol, 1.0 equiv) in CH.sub.2Cl.sub.2 (50 mL), Et.sub.3N
(2.5 mL, 18.4 mmol, 2.0 equiv) was added at rt. After the reaction
solution was stirred at rt for 10 min, 5-bromovaleryl chloride (1.9
g, 9.6 mmol, 1.05 eq) was added. The reaction solution was stirred
at rt for 2 h. The mixture was quenched with H.sub.2O (20 mL) and
extracted with CH.sub.2Cl.sub.2 (50 mL.times.3). The organic layer
was collected, concentrated in vacuo, and the residue was purified
by column chromatography (silica, petroleum ether/EtOAc=1:1) to
give (trans)-1-tert-butyl 4-ethyl
3-(5-bromopentanamido)piperidine-1,4-dicarboxylate 8 as yellow oil
(3.2 g, yield: 80%). ESI-MS (M+H-56).sup.+: 379.0. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta.: 5.99 (d, 1H), 4.39-4.38 (m, 1H), 4.15 (q,
2H), 3.79-3.74 (m, 1H), 3.66-3.60 (m, 1H), 3.41 (t, 2H), 3.30-3.26
(m, 1H), 3.21-3.14 (m, 1H), 2.78-2.74 (m, 1H), 2.19 (t, 2H),
1.99-1.85 (m, 3H), 1.80-1.72 (m, 3H), 1.45 (s, 9H), 1.27 (t,
3H).
[0099] Synthesis of trans-1'-tert-butyl 4'-ethyl
2-oxo-[1,3'-bipiperidine]-1',4'-dicarboxylate. To a solution of
trans-1-tert-butyl 4-ethyl
3-(5-bromopentanamido)piperidine-1,4-dicarboxylate 8 (3.0 g, 6.9
mmol, 1.0 equiv) in THE (20 mL), NaH (276 mg, 6.9 mmol, 1.0 equiv)
was carefully added in small portions at 0.degree. C. The reaction
solution was stirred at reflux condition for 4 h. The mixture was
quenched with H.sub.2O (20 mL), and extracted with EtOAc (30
mL.times.3). The organic layer was collected, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
residue was purified by column chromatography (silica, petroleum
ether/EtOAc=1:2) to give (trans)-1'-tert-butyl 4'-ethyl
2-oxo-[1,3'-bipiperidine]-1',4'-dicarboxylate 9 as a slight yellow
oil (2.1 g, yield: 88%). ESI-MS (M+H-56): 299.1. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta.: 4.10 (q, 4H), 3.38-3.19 (m, 4H),
2.70-2.61 (m, 1H), 2.36-2.31 (m, 2H), 1.95-1.92 (m, 1H), 1.75-1.71
(m, 6H), 1.46 (s, 9H), 1.23 (t, 3H).
Example 2
Preparation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
##STR00031## ##STR00032##
[0101] Synthesis of
trans-1'-tert-butyl-4'-ethyl-3-iodo-2-oxo-[1,3'-bipiperidine]-1',4'-dicar-
boxylate. To the solution of trans-1'-tert-butyl 4'-ethyl
2-oxo-[1,3'-bipiperidine]-1',4'-dicarboxylate 8 (141 mg, 2.58 mmol,
1.0 equiv) in dry toluene (10 mL) at 0.degree. C., TMEDA (0.89 g,
7.7 mmol, 3.0 equiv) and TMSCl (0.6 mg, 1.0 mmol, 2.0 equiv) were
added successively under N.sub.2. After 0.5 h, 12 (0.98 g, 3.87
mmol, 1.5 equiv) was carefully added in small portions. The
reaction solution was stirred at 0.degree. C. to rt for 16 h. The
mixture was diluted with EtOAc (100 mL), washed with saturated
Na.sub.2S.sub.2O.sub.3 (20 mL.times.2) and brine (20 mL), dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
product 9 (2.2 g, Y: 81%) was used directly in the next step
without further purification. ESI-MS (M+H-56).sup.+: 424.9. .sup.1H
NMR (400 MHz, CDCl.sub.3): 4.78-4.73 (m, 1H), 4.19-4.04 (m, 4H),
3.55-3.30 (m, 4H), 3.24-3.16 (m, 2H), 2.73-2.60 (m, 1H), 2.22-2.14
(m, 2H), 1.96-1.78 (m, 2H), 1.70-1.60 (m, 1H), 1.44 (s, 9H), 1.25
(t, J=7.2 Hz, 3H).
[0102] Synthesis of trans-1'-tert-butyl 4'-ethyl
3-((3-chloro-5-(trifluoromethyl)
phenyl)amino)-2-oxo-[1,3'-bipiperidine]-1',4'-dicarboxylate. A 1.0
M solution of lithium bis(trimethyldisilyl)amide in THE (13 mL, 12
mmol, 2.0 equiv) was added through an addition funnel at
10-15.degree. C. to a solution of
3-chloro-5-(trifluoromethyl)aniline (15 g, 78 mmol, 1.2 equiv) in
THE (13 mL). The mixture was allowed to stir at room temperature
for 20 min and a solution of crude
trans-1'-tert-butyl-4'-ethyl-3-iodo-2-oxo-[1,3'-bipiperidine]-1',4'-dicar-
boxylate 9 (3.7 g, 65 mmol, 1.0 equiv) in THE (13 mL) was added
through an addition funnel at 10-15.degree. C. over 30 min. After
addition, the reaction was allowed to stir at the temperature for
30 min. Upon completion, the reaction was cooled to 5.degree. C.
and quenched slowly with water (10 mL), keeping the temperature
below 20.degree. C. The quenched reaction was extracted with EtOAc
(2.times.30 mL). The combined organic layers were washed with
saturated brine (30 mL), dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The resulting crude product was purified
over silica gel eluting with a gradient of 10% to 75% of EtOAc in
heptanes to give the desire product 10. ESI-MS (M+H-56).sup.+:
463.1. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 6.92 (s, 1H),
6.71-6.69 (m, 2H), 4.17-4.06 (m, 4H), 3.78-3.68 (m, 2H), 3.46-3.36
(m, 3H), 3.23-3.07 (m, 2H), 2.73-2.65 (m, 1H), 2.44-2.37 (m, 1H),
2.03-1.85 (m, 3H), 1.71-1.61 (m, 2H), 1.46 (s, 9H), 1.27-1.19 (m,
3H).
[0103] Synthesis of
trans-1'-(tert-butoxycarbonyl)-3-((3-chloro-5-(trifluoromethyl)
phenyl) amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic acid. To a
solution of trans-1'-tert-butyl 4'-ethyl
3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-1-
',4'-dicarboxylate 10 (180 mg, 0.33 mmol, 1.0 equiv) in EtOH (5 mL)
was added NaOH (40 mg, 0.99 mmol, 3.0 equiv) and solution was
stirred at 80.degree. C. for 1 h. The solvent was concentrated in
vacuo and the residue was suspended in water (10 mL) and adjusted
to pH=6 with HCl (4 N). The precipitate was filtered to afford
(trans)-1'-(tert-butoxycarbonyl)-3-((3-chloro-5-(trifluoromethyl)phenyl)a-
mino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic acid 11 (150 mg, Y:
82%) as yellow solid which was used next step without further
purification. ESI-MS (M+H-85).sup.+: 463.1. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta.: 6.85 (s, 1H), 6.82 (s, 1H), 6.78 (s, 1H),
4.12-3.96 (m, 4H), 3.53-3.37 (m, 2H), 3.11-3.04 (m, 2H), 2.75-2.67
(m, 1H), 2.24-2.18 (m, 1H), 1.98-1.89 (m, 3H), 1.71-1.58 (m, 2H),
1.44 (s, 9H).
[0104] Synthesis of trans-tert-butyl
4'-carbamoyl-3-((3-chloro-5-(trifluoromethyl)
phenyl)amino)-2-oxo-[1,3'-bipiperidine]-1'-carboxylate. To the
solution of trans
1'-(tert-butoxycarbonyl)-3-((3-chloro-5-(trifluoromethyl)phenyl)-
amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic acid 11 (70 mg, 0.14
mmol, 1.0 equiv) in DMF (2 mL), was added NH.sub.4Cl (22 mg, 0.41
mmol, 3.0 equiv), HBTU (103 mg, 0.270 mmol, 2.0 equiv) and DIPEA
(52 mg, 0.41 mmol, 3.0 equiv). The reaction solution was stirred at
rt for 16 h, diluted with EtOAc (10 mL) and washed with water (5
mL) and brine (5 mL). The organic phase was separated and
concentrated in vacuo to afford a crude oil which was purified by
pre-HPLC (MeOH/H.sub.2O with 0.05% TFA as mobile phase) to give the
compound
(trans)-tert-butyl4'-carbamoyl-3-((3-chloro-5-(trifluoromethyl)
phenyl) amino)-2-oxo-[1,3'-bipiperidine]-1'-carboxylate 12 (60 mg,
yield: 86%) as a light solid. ESI-MS (M+H-56).sup.+: 463.1. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta.: 6.87-6.86 (m, 1H), 6.84-6.83 (m,
1H), 6.80 (s, 1H), 4.11-4.03 (m, 3H), 3.53-3.35 (m, 2H), 3.20-3.08
(m, 2H), 2.77-2.74 (m, 1H), 2.25-2.18 (m, 1H), 1.99-1.88 (m, 3H),
1.70-1.60 (m, 2H), 1.46 (s, 9H).
[0105] Synthesis of
trans-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperid-
ine]-4'-carboxamide. To the solution of trans-tert-butyl
4'-carbamoyl-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bi-
piperidine]-1'-carboxylate 12 (60 mg, 0.11 mmol) in
CH.sub.2Cl.sub.2 (1.0 mL) was added CF.sub.3CO.sub.2H (1.0 mL) at
rt. The reaction mixture was stirred at rt for 2 h, concentrated in
vacuo to give desired product 13 (43 mg, 90%) which was used
directly in the next step without further purification. ESI-MS
(M+H).sup.+: 419.0.
[0106] Synthesis of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. To a
solution of
trans-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperid-
ine]-4'-carboxamide 13 (42 mg, 0.10 mmol, 1.0 equiv) in 1-butanol
(2 mL), 6-chloro-5-fluoropyrimidin-4-amine (18 mg, 0.12 mmol, 1.2
equiv) was added DIPEA (26 mg, 0.20 mmol, 2.0 equiv). The reaction
solution was stirred at 120.degree. C. for 16 h. The mixture was
diluted with EtOAc (20 mL), washed with H.sub.2O (10 mL) and brine
(10 mL), dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The crude was by purified by pre-HPLC (MeOH/H.sub.2O with
0.05% TFA as mobile phase) to give the compound
(trans)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorometh-
yl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 (44
mg, yield: 83%) as a yellow solid. ESI-MS (M+H).sup.+: 530.0. HPLC:
(214 nm: 100%, 254 nm: 100%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta.: 7.97 (s, 1H), 6.84 (s, 1H), 6.81 (s, 1H), 6.76 (s, 1H),
4.58-4.52 (m, 2H), 4.09-4.03 (m, 1H), 3.52-3.35 (m, 3H), 3.29-3.27
(m, 4H), 3.12-3.05 (m, 1H), 2.24-2.17 (m, 1H), 2.02-1.91 (m, 3H),
1.80-1.63 (m, 2H).
##STR00033##
[0107]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)
phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. The mixture
of four diastereomers of compound 14 was separated into three peaks
by SFC (IA(2.times.15 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar,
60 ml/min) and the title compound corresponded to peak 3. LCMS
(Agilent460, 254 nm): ES (+) MS m/e=530.1 (M+1) @ 1.20 min. .sup.1H
NMR (400 MHz, DMSO-d6) .delta.: 7.77 (d, J=2.01 Hz, 1H), 7.38 (br.
s., 1H), 6.94 (s, 2H), 6.75-6.87 (m, 2H), 6.41-6.66 (m, 3H), 4.29
(br. s., 1H), 4.23 (d, J=13.05 Hz, 1H), 3.96-4.18 (m, 2H), 3.44
(td, J=6.15, 12.30 Hz, 1H), 3.24-3.33 (m, 1H), 3.10 (br. s., 1H),
2.88 (br. s., 1H), 2.82 (t, J=12.30 Hz, 1H), 2.13 (qd, J=5.94,
12.30 Hz, 1H), 1.74-1.93 (m, 3H), 1.58-1.74 (m, 1H), 1.41-1.58 (m,
1H).
##STR00034##
[0108]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers of compound 14 was separated into
three peaks by SFC (IA(2.times.15 cm), 30% EtOH (0.1%
DEA)/CO.sub.2, 100 bar, 60 ml/min) and the title compound
corresponded to peak 2. LCMS (Agilent460, 254 nm): ES (+) MS
m/e=530.1 (M+1) @ 1.19 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta.:
7.77 (d, J=1.76 Hz, 1H), 7.39 (br. s., 1H), 6.98 (s, 1H), 6.96 (s,
1H), 6.72-6.88 (m, 2H), 6.57 (s, 2H), 6.54 (d, J=7.78 Hz, 1H),
4.05-4.33 (m, 4H), 3.37 (t, J=6.27 Hz, 2H), 3.11 (br. s., 1H), 2.94
(br. s., 1H), 2.82 (t, J=12.30 Hz, 1H), 2.02-2.16 (m, 1H),
1.75-1.92 (m, 3H), 1.57-1.74 (m, 1H), 1.36-1.54 (m, 1H).
##STR00035##
[0109]
(3S,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers of compound 14 was separated into
three peaks by SFC (IA(2.times.15 cm), 30% EtOH (0.1%
DEA)/CO.sub.2, 100 bar, 60 ml/min). Peak 1 of 3 was further
purified SFC (AD-H (2.times.15 cm), 30% iPrOH (0.1% DEA)/CO.sub.2,
100 bar, 60 ml/min) to afford the title compound. LCMS (Agilent
460, 254 nm): ES (+) MS m/e=530.1 (M+1) @ 1.20 min. .sup.1H NMR
(400 MHz, DMSO-d6) .delta.: 7.77 (d, J=1.76 Hz, 1H), 7.38 (br. s.,
1H), 6.94 (s, 2H), 6.83 (s, 1H), 6.80 (s, 1H), 6.42-6.66 (m, 3H),
4.18-4.47 (m, 2H), 3.95-4.18 (m, 2H), 3.39-3.52 (m, 1H), 3.24-3.31
(m, 1H), 3.10 (br. s., 1H), 2.88 (br. s., 1H), 2.82 (t, J=12.30 Hz,
1H), 2.13 (qd, J=5.91, 12.39 Hz, 1H), 1.73-1.92 (m, 3H), 1.58-1.73
(m, 1H), 1.42-1.58 (m, 1H).
##STR00036##
[0110]
(3R,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers of compound 14 was separated into
three peaks by SFC (IA(2.times.15 cm), 30% EtOH (0.1%
DEA)/CO.sub.2, 100 bar, 60 ml/min). Peak 1 of 3 was further
purified SFC (AD-H (2.times.15 cm), 30% iPrOH (0.1% DEA)/CO.sub.2,
100 bar, 60 ml/min) to afford the titled compound. LCMS (Agilent
460, 254 nm): ES (+) MS m/e=530.1 (M+1) @ 1.20 min. .sup.1H NMR
(400 MHz, DMSO-d6) .delta.: 7.77 (d, J=1.76 Hz, 1H), 7.39 (br. s.,
1H), 6.98 (s, 1H), 6.96 (s, 1H), 6.73-6.88 (m, 2H), 6.57 (s, 2H),
6.54 (d, J=7.78 Hz, 1H), 4.05-4.35 (m, 4H), 3.37 (t, J=6.15 Hz,
2H), 3.12 (br. s., 1H), 2.94 (br. s., 1H), 2.82 (t, J=12.30 Hz,
1H), 2.09 (sxt, J=5.80 Hz, 1H), 1.74-1.92 (m, 3H), 1.56-1.73 (m,
1H), 1.36-1.52 (m, 1H).
Example 3
Alternative Synthesis of
(3R,3'R,4's)-1'-(6-Amino-5-Fluoropyrimidin-4-Yl)-3-((3-Chloro-5-(trifluor-
omethyl) phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
[0111] In addition to the methods described in Example 2,
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluor-
omethyl) phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
(compound I-1) was also synthesized according to Scheme 6.
##STR00037## ##STR00038## ##STR00039## ##STR00040##
[0112] 1-tert-Butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate 3-2.
To a solution of 3-1 (5.0 kg, 19.1 mol, 1.0 equiv) in EtOH (50 L)
under N.sub.2 was added (Boc).sub.2O (4.2 kg, 19.1 mol, 1.0 equiv),
Et.sub.3N (1.9 kg, 19.1 mol, 1.0 equiv) and 10% Pd(OH).sub.2/C (250
g, 10% w/w). After evacuated and refilled with hydrogenation three
times, the mixture was stirred under 1 atm of hydrogen at
50.degree. C. for 15 hr. LC-MS indicated completely consumption of
3-1. After the mixture was cooled to ambient temperature, the
catalyst was filtered through a layer of celite and washed with
EtOH (2.5 L). The filtrate was concentrated in vacuo to afford
crude 3-2 (5.2 kg) as an oil, which was used in next step without
further purification.
##STR00041##
[0113] (S)-1-tert-butyl 4-ethyl
3-((1-phenylethyl)amino)-5,6-dihydropyridine-1,4 (2H)-dicarboxylate
(3-3). To a 100 L reactor equipped with Dean-Stark apparatus was
charged toluene (20 L), crude compound 3-2 (5.2 kg, 19.1 mol, 1.0
equiv) rinsed with toluene (30 L), pTSA (329 g, 0.2 mol, 0.01
equiv), and S-(-)-.alpha.-methylbenzylamine 0.95 kg, 16.2 mol, 0.85
equiv). The mixture was heated to reflux with a nitrogen blanket
and the water was removed through Dean-Stark. After 18 hours, LC-MS
indicated complete consumption of 3-2. The mixture was then cooled
to the ambient temperature. The insolubles were removed by
filtration, and the filtrate was concentrated in vacuo to dryness
to afford crude 3-3 as a thick oil. This crude product was used in
the next step without further purification. 3-10% of amide
byproduct formed in this reaction and its structure was tentatively
assigned based on LC-MS data.
##STR00042##
[0114] (3R)-1-tert-butyl 4-ethyl
3-(((S)-1-phenylethyl)amino)piperidine-1,4-dicarboxylate (3-4). To
a 100 L reactor charged with NaBH.sub.4 (1.16 kg, 30.5 mol, 2.0
equiv) and anhydrous THE (60 L) under nitrogen was added TFA (10.5
kg, 92 mol, 6.0 equiv) slowly over 30 min while maintaining
temperature at 0-5.degree. C. The mixture was then cooled to
-45.degree. C. In a separation reactor, crude product 3-3 was
dissolved in anhydrous acetonitrile (30 L), which was added slowly
to the above solution of NaBH.sub.4/TFA while maintaining the
internal temperature between -45.about.-30.degree. C. The mixture
was stirred at -45.degree. C. for 1 h, after which time, HPLC
indicated complete consumption of compound 3-3. The mixture was
slowly diluted with ice water (50 kg) and the mixture was then
warmed to 10.degree. C. The product was extracted with EtOAc
(2.times.40 L) and the combined organic layers were washed with
saturated NaHCO.sub.3 solution (20 L). pH of the aqueous was
.about.8. The organic layers were dried (Na.sub.2SO.sub.4) and
concentrated in vacuo to nearly dryness to afford a residue which
was further azeotroped with MeOH (10 L.times.3) to remove excess
EtOAc. In the end, a 10 L solution of crude 3-4 in MeOH was
obtained, which was used directly in the subsequent step without
further purification. ESI-MS (M+H-1).sup.+: 377.2. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta.: 7.31-7.22 (m, 5H), 4.20 (q, 2H),
4.11-3.86 (m, 3H), 3.15 (s, 1H), 3.00-2.90 (m, 2H), 2.64 (d, 2H),
1.87-1.85 (m, 1H), 1.68 (s, 1H), 1.50-1.25 (m, 15H).
##STR00043##
[0115]
(3R)-1-(tert-butoxycarbonyl)-3-(((S)-1-phenylethyl)amino)piperidine-
-4-carboxylic acid (3-5). To a 100 L reactor were charged a with
THF/MeOH (1:1, 80 L), was added a solution of LiOH H.sub.2O (2.5
kg, 60 mol, 4.0 equiv) in water (10 L) and a solution of crude 3-4
in MeOH (10 L) from the above step. The resulting mixture was
stirred at 22.degree. C. for 18 hours, at which time LC/MS
indicated complete consumption of starting material 3-4. The
solution was diluted with MTBE (40 L) and stirred for 20 min. The
aqueous layer was separated, cooled to 0.degree. C. and neutralized
with 3N HCl solution to pH between 7-8, while maintaining the
internal temperature below 10.degree. C. The solution was washed
with DCM (5.times.30 L) or until the LC/MS indicated no product 3-5
remained in the aqueous layer. The combined organic layers were
concentrated in vacuo to dryness, suspended in EtOAc and petroleum
ether (2:1, 10 L) and stirred for 2 hours, the solids were
filtered, washed by petroleum ether (5 L) and dried under vacuum at
50.degree. C. for 18 hours to give product (3.5 Kg, 53% yield) as a
solid with 95% purity. Compound 3-5 is a mixture of .about.30:70
trans/cis at C-4 and .about.93:7 R:S at C-3. The average overall
yield from 3-1 is 43-55%. ESI-MS (M+H-1).sup.+: 349.2. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta.: 8.22-8.06 (m, 5H) 4.11 (m, 1H),
3.86-3.82 (m, 1H), 3.59-3.56 (m, 1H), 2.79-2.65 (m, 1H), 3.22-2.62
(m, 2H), 2.06-2.16 (m, 12H).
##STR00044##
[0116]
(3R)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-(((S)-1-phenylethyl)amino-
)piperidine-4-carboxylic acid (3-7). To a 50 L reactor was charged
with 10 L of 2N HCl and 3-5 (850 g, 2.44 mol, 1.0 equiv). The
mixture was warmed to 30.degree. C. and stirred for 2 hours, at
which time HPLC indicted complete consumption of starting 3-5. The
solution was diluted with MTBE (4 L) and stirred for 20 min, layers
were separated and to the aqueous layer was added solid
K.sub.2CO.sub.3 (660 g) over 1 hour to pH .about.7. Additional
K.sub.2CO.sub.3 (660 g, 4.8 mol, 2.0 equiv) was added following by
6-chloro-5-fluoropyrimidine-4-ylamine (360 g, 2.44 mole 1.0 equiv)
and 1,4-dioxane (5 L). The mixture was heated to gentle reflux at
100.degree. C. and stirred at this temperature for 16 hours. HPLC
indicated <2% of compound 3-6 remained. The mixture was washed
with DCM (2.times.5 L) and the organic wash solutions were
discarded. The aqueous layer was treated with active carbon (425 g)
by stirring the slurry for 1 hour at 30.degree. C. followed by
filtration through diatomite. This active carbon treatment was
repeated. The resulting aqueous solution was neutralized to pH
.about.7 with concentrated HCl, and stirred at 22.degree. C. for 3
hours, the resulting slurry was filtered and the wet cake was
washed with washed with 1,4-dioxane/water (1:1, 1.2 L), dried under
vacuum at 50.degree. C. for 18 hr until KF .about.0.5%. of product
3-7 was obtained as a pale white solid (690 g, 81% yield) with
purity of 98.6%. The product contains a mixture of 1:9 cis/trans
iomers at the C3 and C4 positions. ESI-MS (M+H-1).sup.+: 460.2.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 8.49 (d, J=2.01 Hz, 1H),
8.21-8.14 (m, 5H) 4.94-4.90 (m, 1H), 4.63 (d, J=11.55 Hz, 1H), 4.42
(m, 1H), 4.03 (m, 2H), 3.59-3.72 (m, 3H), 2.84-2.93 (m, 1H),
2.20-2.31 (m, 1H), 2.15 (d, J=6.78 Hz, 3H).
##STR00045##
[0117]
(3R)-3-amino-1-(6-amino-5-fluoropyrimidin-4-yl)piperidine-4-carboxy-
lic acid (3-8). To a 10 L reaction were charged under N.sub.2,
i-PrOH (3.5 L), H.sub.2O (3.5 L), 3-7 (1.0 equiv, 0.97 mol, 350 g),
potassium fluoride mono hydrate (290 g, 3.0 eq, 3.0 mol) and 35 g
of 20% Pd(OH).sub.2/C (10% v/w). After evacuated/refilled with
hydrogen three times, the mixture was warmed to 40-50.degree. C.
and vigorously stirred at that temperature under 1 atmosphere of
hydrogen. After 18 hours, LC/MS indicated <1% of starting
material 3-7 remained. The mixture was purged with N.sub.2 for 20
min, cooled to 22.degree. C., and filtered. Both the wet cake and
filtrate contained the product and processed separately.
[0118] The filtrate was concentrated in vacuo at 50.degree. C. to a
volume of -200 mL. After cooled to 20.degree. C. and stirred at
this temperature for 2 hours, a slurry was obtained, and the solid
was filtered, washed with water (400 mL) and dried under vacuum and
at 50.degree. C. to give product 3-8 (65 g). The wet cake from the
reaction filtration was stirred in 1 N HCl (1 L) for 2 hours to
dissolve the product and the remaining catalyst solid was then
removed by filtration. The acidic filtrate was neutralized with
solid LiOH to pH .about.7 to precipitate the product 3-8. The
product was washed with water (200 mL), dried under vacuum and at
50.degree. C. to give 120 g of product. A total of 185 g of product
was obtained with 98.7% purity and in 75% yield based on H NMR. All
the mother liquors were combined and concentrated to a volume of
.about.400 mL result in a slurry, filtration, wash with water and
drying gave additional 64 g solid with 50% purity. .sup.1H NMR (400
MHz, D20): .delta. 7.77 (s, 1H) 4.12 (d, J=14.05 Hz, 1H), 4.01 (d,
J=13.05 Hz, 1H), 3.26 (d, J=13.80 Hz, 1), 2.99-3.10 (m, 1H),
2.64-2.73 (m, 1H), 1.98 (dd, J=3.39, 14.18 Hz, 1H), 1.74-1.87 (m,
1H).
##STR00046##
[0119]
((3R,3'R)-1'-(tert-butoxycarbonyl)-3-((3-chloro-5-(trifluoromethyl)-
phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic acid (3-10).
To a solution of 3-8 (440 g, 1.9 mole, 1.0 equiv) in DMSO (10 L)
was added 3-8 A sequentially (640 g, 1.9 mole, 1.0 equiv) and
sodium triacetoxyborohydride (STAB, 402.0 g, 3.8 mole, 2 equiv) and
Et.sub.3N (190 g, 1.9 mol, 1.0 equiv). The mixture was heated to
50.degree. C. and stirred for 3 hours to show complete conversion
by HPLC to intermediate 3-9.
[0120] The solution was diluted with MeOH (182 g, 5.7 mol, 3.0 eq)
to quench the excess of STAB, and the reaction was heated to
70.about.80.degree. C. After 16 hours, HPLC indicated 22% of
product 3-10 formed and 61% intermediate 3-9 remained and chiral
HPLC indicated 3% lactam epimer. The mixture was held at
70-80.degree. C. for additional 24 hours to give 50% 3-10, 35% 3-9,
and 7% lactam epimer. After another 40 hours stirring, 80% 3-10
formed, 4% 3-9 remained, and the lactam epimer increased to 14%.
The mixture was cooled to 22.degree. C., and quenched with 2N
NH.sub.4Cl solution (5 L) to give a slurry mixture. After 30 minute
stirring, the mixture was filtered and the wet cake was washed with
water (3 L), dried under vacuum and at 55.degree. C. until
KF<0.1. Crude 3-10 was obtained as a brown solid (850 g, 97.7%);
chiral HPLC indicted 12.5% lactam epimer. This product was used
directly without further purification
##STR00047##
[0121]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic
acid (3-10-trans). To a 10 L reactor was charged under N.sub.2 with
3-10 (850 g, 1.9 mol, 1.0 equiv) in DMF (4.25 L, 5 v/w) to give a
clear solution, was added 4-dimethylaminopyridine (DMAP 116 g, 0.95
mol, 0.5 equiv) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDCI, 36.5 g, 0.19 mol, 0.1 equiv). After the mixture was stirred
at 15 to 22.degree. C. for about 1 hour, additional EDCI (36.5 g,
0.19 mol, 0.1 equiv) was added and stirred for another 1 hour. HPLC
indicated a 69:1 trans/cis mixture. The product 3-10-trans was not
isolated and was converted to compound I-1 in one-pot. .sup.1H NMR
(300 MHz, DMSO d6): .delta. 1.47-1.55 (m, 1H), 1.63-1.68 (m, 1H),
1.81-1.87 (m, 1H), 1.90-1.97 (m, 1H), 2.93-3.19 (m, 1H), 3.16-3.23
(m, 1H), 3.33-3.45 (m, 2H) 4.07-4.33 (m, 3H), 6.80 (m, 1H),
6.94-6.98 (m, 1H), 7.10-7.16 (m, 2H), 7.91 (s, 1H).
[0122]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
(I-1). To the above reaction mixture, was charged at 22.degree. C.,
with O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU, 600 g, 1.9 mol, 1.0 equiv),
N,N-diisopropylethylamine (DIPEA, 1.0 kg, 9.5 mol, 5.0 equiv) and
finally NH.sub.4Cl (260 g, 5.7 mol, 3.0 equiv). The resulting
mixture was stirred at 15.degree. C. for 1 hour, HPLC indicated
complete consumption of 3-10-trans, the mixture was poured into
brine (25 L) and extracted with EtOAc (2.times.2 L). The combined
organics were washed with brine (2.times.2 L) and concentrated in
vacuo below 45.degree. C. to dryness to result in a crude I-1,
which was purified by chromatograph with EtOAc/petroleum ether/MeOH
(1:1:0 to 50:50:10) to give three fractions, which contained 316 g,
98.8% chemical purity and 10.8% epimer, 160 g, 82.3% chemical
purity and 17.5% epimer and 180 g, 61% purity and 11.3% epimer,
respectively. The above first two fractions were combined and
further purified by prep-HPLC to give 200 g product with >99%
purity and <1% epimer. .sup.1H NMR (400 MHz, DMSO d6): .delta.
1.48-1.53 (m, 1H), 1.66-1.69 (m, 1H), 1.77-1.79 (m, 3H), 2.11-2.16
(m, 1H), 2.80-2.88 (m, 2H), 3.11 (s, 1H), 3.42-3.48 (m, 1H),
4.0-4.25 (m, 4H), 6.58 (s, 3H), 6.80-6.85 (d, J=10.2, 2H), 6.95 (s,
2H), 7.40 (s, 1H), 7.77 (s, 1H).
Example 4
Alternative Syntheses of
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluor-
omethyl) phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
[0123] In addition to the methods described in Examples 2 and 3,
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluor-
omethyl) phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
(compound I-1) was also synthesized according to Scheme 6.
##STR00048## ##STR00049##
[0124] (3R)-3-amino-1-(tert-butoxycarbonyl)piperidine-4-carboxylic
acid (4-L-6). To a 10 L reactor charged under nitrogen with
compound 4-5 (100 g, 0.287 mole), MeOH(6 L, 60 v/w) and 10 g 20%
Pd(OH).sub.2/C. The reactor was evacuated/refilled with hydrogen
three times and the mixture was warmed to 40-50.degree. C. while
stirring under 3 Mpa of hydrogen for 40 hours. LC/MS indicated
complete consumption of starting material 4-5. The mixture was
cooled to 22.degree. C. and filtered, and the filtrate was
concentrated in vacuo to dryness to afford a solid product. This
crude product was slurried in EtOH (500 mL) at 22.degree. C. for 2
hours, filtered and dried under vacuum at 50.degree. C. to afford a
85% yield of product 4-L-6 (60 g, 0.245 mole) as a white solid.
##STR00050##
[0125]
(3R)-1-(tert-butoxycarbonyl)-3-(((R)-4-((3-chloro-5-(trifluoromethy-
l)phenyl)amino)-5-ethoxy-5-oxopentyl)amino)piperidine-4-carboxylic
acid (4-L-8). To a solution of 4-L-6 (48.4 g, 0.197 mole) in DMSO
(450 mL) was added Et.sub.3N (20.2 g, 0.199 mole, 1 equiv), 3-8 A
(67.4 g, 0.199 mole, 1 equiv) and sodium triacetoxyborohydride
(STAB, 84.8 g, 0.40 mole, 2.0 equiv). The mixture was heated to
50.degree. C. over 30 min and stirred at that temperature for 3
hours. LC/MS indicated consumption of most of starting material
4-L-6 and formation of 4-L-8.
[0126] The reaction was quenched by adding EtOH (35 mL) and
stirring at 50.degree. C. for 30 min. The mixture was heated at
75-85.degree. C. for 3 days. The mixture was cooled to 18.degree.
C. and transferred slowly into water (6 L) while vigorously
stirring to afford a slurry. After 2 hours, the solids were
filtered and washed with water (3.times.3 L), dried under vacuum at
60-70.degree. C. for 24 hours to give 4-L-9 (114 g) as a brown
solid. The solid was used directly in the subsequent step.
##STR00051##
[0127]
(3R,3'R,4'S)-1'-(tert-butoxycarbonyl)-3-((3-chloro-5-(trifluorometh-
yl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylicacid
(4-L-9-trans). To a solution of crude 4-L-9 (100 g), in DMF (500
mL) was added 4-dimethylaminopyridine (11 g, 0.09 mole, 0.5 equiv)
and stirred at 20.degree. C. for 10 min.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (7.0 g, 0.036 mole,
0.2 equiv) was added and the reaction was stirred 20.degree. C. for
3 hours. HPLC indicated a ratio of 57:43 cis/trans mixture and
additional EDAC (3.5 g, 0.018 mole, 0.1 equiv) was added. After 5
hours, HPLC indicated complete conversion to 4-L-9-trans. The
mixture was transferred to water (2.25 L) slowly and the mixture
was extracted with EtOAc (2.times.500 mL), and the organic layers
were washed with brine (500 mL) and water (500 mL), concentrated in
vacuo to dryness to give crude 4-L-9-trans (100 g) as a brown
solid. The crude was dissolved in EtOAc (135 mL) at 60.degree. C.
and then cooled to 20.degree. C. over 1 hour followed by adding 50
mL petroleum ether. The mixture was aged for 2 hours. The solids
were filtered and washed with 3:1 EtOAc/petroleum ether (50 mL),
dried under vacuum at 50.degree. C. for 16 hours to give
4-L-9-trans (23 g, 22% yield with 99% purity). .sup.1H NMR (400
MHz, DMSO-d6) .delta. 6.94 (s, 2H), 6.81 (s, 1H), 6.54-6.61 (m,
1H), 3.99-4.08 (m, 1H), 3.42-3.38 (m, 2H), 2.07-2.16 (m, 1H),
1.74-1.92 (m, 3H), 1.39 (s, 9H).
##STR00052##
[0128]
(3R,3'R,4'S)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1-
,3'-bipiperidine]-4'-carboxylic acid hydrochloride (4-L-10 trans).
To a solution of 0.5N HCl in EtOAc (76 mL) was added 4-L-9 trans
(20 g, 38 mmol) and heated at 20.degree. C. for 18 h to give a
slurry. The solid was filtered, washed with EtOAc (5 mL) and dried
under vacuum at 45.degree. C. for 18 h to afford 4-L-10 as the HCl
salt (17 g, 97% yield).
##STR00053##
[0129]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic
acid (3-10-trans). A solution of 4-L-10 (2.0 g, 4.38 mole),
6-chloro-5-fluoro-pyrimidin-4-ylamine (711 mg, 4.82 mmole, 1.1
equiv), DIPEA (1.52 mL, 8.77 mole, 2 eq.) in 40 mL nBuOH was heated
to 130-140.degree. C. for 72 h. The mixture was cooled to
22.degree. C. and concentrated in vacuo to afford a residue which
purified by column to give 3-10-trans (1.1 g, 47%). A relatively
minor amount of epimer
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluor-
omethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic acid
was also observed. Intermediate 3-10-trans can be converted to
compound I-1 via procedure described above.
[0130] Compound I-1 was also synthesized according to Scheme 8.
##STR00054## ##STR00055##
[0131] The synthesis of (R)-tert-butyl
1-(3-chloro-5-(trifluoromethyl)phenyl)-5-oxopyrrolidine-2-carboxylate
4-e was synthesized using a similar procedure as in Phillips, D.
P.; Zhu, X. --F.; Lau, T. L.; Yang, K.; Liu, H. Tetrahedron
Letters, 2009, 50, 7293, whereby the (S)-methyl
5-oxopyrrolidine-2-carboxylate and 1-chloro-4-iodobenzene were
substituted for the (R)-tert-butyl 5-oxopyrrolidine-2-carboxylate
and 1-chloro-3-iodo-5-(trifluoromethyl)benzene.
[0132] (2R)-tert-butyl
1-(3-chloro-5-(trifluoromethyl)phenyl)-5-hydroxypyrrolidine-2-carboxylate-
. An anhydrous solution of 4-e (11 g, 30 mmol) in Me-THF (100 mL)
was cooled to -35.degree. C. under an atmosphere of nitrogen. A
solution of DIABL-H (5.9 g, 42 mmol) in toluene (42 mL) was added
dropwise while maintaining the temperature at -35.degree. C. The
reaction was monitored by HPLC and upon completion a solution of 1N
Rochell salt (100 mL) was added while maintaining the reaction
temperature below 0.degree. C. The organic phase was separated,
washed with 1N Rochell salt (50 mL.times.3) and separated, diluted
with Et.sub.3N (4 mL), dried (Na.sub.2SO.sub.4) and concentrated in
vacuo to afford 4-f (8.3 g) as an oil.
[0133]
(3R)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-(((R)-5-(tert-butoxy)-4-(-
(3-chloro-5-(trifluoromethyl)
phenyl)amino)-5-oxopentyl)amino)piperidine-4-carboxylic acid. A
solution of 4-f (37.4 g, 0.146 mmol) in DMF (700 mL) was treated
with 3-8 (40.2 g, 0.11 mmol), Et.sub.3N (10.1 g, 0.1 mmol) STAB
(42.4 g, 0.2 mmol) and the mixture was heated to 55.degree. C. for
5 h. The reaction was diluted with water (2.5 L), extracted with
EtOAc (500 mL.times.3), the organic phases were combined and washed
with brine, separated, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo to afford 4-a (40.2 g) as solid which was used without any
additional purification.
[0134]
(3R)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-(((R)-4-carboxy-4-((3-chl-
oro-5-(trifluoromethyl)phenyl)amino)butyl)amino)piperidine-4-carboxylic
acid. To a solution of 5 N HCl (250 mL) was added t-butyl ester 4-a
and the suspension was heated to 55.degree. C. for 5 h while the
hydrolysis was monitored by HPLC. Upon complete formation of the
product the water was removed in vacuo resulting in a solid 4-b
which was dried under vacuum and used without any additional
purification.
[0135]
(3R,3'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(triflu-
oromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxylic
acid. To a solution of acid 4-b (55 g, 0.1 mol) in DMF (500 mL) was
added a DIEA (64.5 g, 0.5 mol), CDI (32.5 g, 0.2 mol) at 0.degree.
C. The solution was stirred for 1.5 h at 0.degree. C., diluted with
water (3 L), adjusted to a pH 3 with HCl and extracted with EtOAc
(2 L.times.3). The organic phase were combined, dried
(Na.sub.2SO.sub.4) and concentrated in vacuo to afford 4-c (48
g).
[0136] The remaining steps to compound I-1 are completed via
procedures described above.
Example 5
Synthesis of trans-tert-butyl
3-((3-chloro-5-(trifluoromethyl)phenyl)
amino)-4'-(methylcarbamoyl)-2-oxo-[1,3'-bipiperidine]-1'-carboxylate
##STR00056##
[0138] Synthesis of trans-tert-butyl
3-((3-chloro-5-(trifluoromethyl)phenyl)
amino)-4'-(methylcarbamoyl)-2-oxo-[1,3'-bipiperidine]-1'-carboxylate.
A similar procedure was used as described for the synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorome-
thyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 to
afford the crude material which was purified by pre-HPLC
(MeOH/H.sub.2O with 0.05% NH.sub.3.H.sub.2O as mobile phase) to
give the title compound (360 mg, yield: 67%) as a yellow solid.
ESI-MS (M+H).sup.+: 544.18. HPLC: (214 nm: 100.0%, 254 nm: 100.0%).
.sup.1H NMR (400 MHz, CD.sub.3OD) (mixture of isomers) .delta.:
7.69-7.68 (m, 1H), 6.78 (s, 1H), 6.75 (s, 1H), 6.71 (s, 1H),
4.39-4.36 (m, 2H), 4.09-4.03 (m, 1H), 3.53-3.31 (m, 3H), 3.20-3.10
(m, 1H), 2.99-2.92 (m, 1H), 2.55 (s, 3H), 2.28-2.19 (m, 1H),
1.96-1.77 (m, 5H), 1.68-1.58 (m, 1H).
##STR00057##
[0139]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N-methyl-2-oxo-[1,3'-bipiperidine]-4'-carboxam-
ide. The mixture of four diastereomers was separated into two peaks
by SFC (AD-H (2.times.15 cm), 50% 1:1 IPA:methanol (0.1%
DEA)/C.sub.2, 100 bar, 60 ml/min). Peak 2 was further purified by
SFC separation (AD-H (2.times.15 cm), 30% iPrOH (0.15%
DEA)/CO.sub.2, 100 bar, 60 ml/min) to afford the title compound.
LCMS (Agilent 460, 254 nm): ES (+) MS m/e=544.1 (M+1) @ 1.24 min.
.sup.1H NMR (400 MHz, DMSO-d6) .delta.: 7.72-7.85 (m, 2H), 6.92 (s,
2H), 6.81 (s, 1H), 6.43-6.64 (m, 3H), 4.34 (br. s., 1H), 4.23 (d,
J=13.05 Hz, 1H), 3.93-4.19 (m, 2H), 3.37-3.49 (m, 1H), 3.22-3.30
(m, 1H), 3.13 (br. s., 1H), 2.84 (t, J=12.05 Hz, 2H), 2.57 (d,
J=4.52 Hz, 3H), 2.13 (qd, J=6.05, 12.45 Hz, 1H), 1.60-1.89 (m, 4H),
1.40-1.58 (m, 1H).
##STR00058##
[0140]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N-methyl-2-oxo-[1,3'-bipiperidine]-4'-carboxam-
ide. The mixture of four diastereomers was separated into two peaks
by SFC (AD-H (2.times.15 cm), 50% 1:1 IPA:methanol (0.1%
DEA)/C.sub.2, 100 bar, 60 ml/min). Peak 2 was further purified by
SFC separation (AD-H (2.times.15 cm), 30% iPrOH (0.15%
DEA)/CO.sub.2, 100 bar, 60 ml/min) to afford the title compound.
LCMS (Agilent 460, 254 nm): ES (+) MS m/e=544.1 (M+1) @ 1.24 min.
.sup.1H NMR (400 MHz, DMSO-d6) .delta.: 7.83 (q, J=4.60 Hz, 1H),
7.77 (d, J=1.76 Hz, 1H), 6.97 (d, J=6.78 Hz, 2H), 6.81 (s, 1H),
6.58 (s, 2H), 6.53 (d, J=7.78 Hz, 1H), 4.23 (d, J=13.05 Hz, 2H),
3.90-4.19 (m, 2H), 3.14 (br. s., 1H), 2.92 (br. s., 1H), 2.74-2.90
(m, 1H), 2.55 (d, J=4.52 Hz, 3H), 2.00-2.18 (m, 1H), 1.74-1.89 (m,
3H), 1.56-1.74 (m, 1H), 1.34-1.50 (m, 1H).
##STR00059##
[0141]
(3S,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N-methyl-2-oxo-[1,3'-bipiperidine]-4'-carboxam-
ide. The mixture of four diastereomers was separated into two peaks
by SFC (AD-H (2.times.15 cm), 50% 1:1 IPA:methanol (0.1%
DEA)/CO.sub.2, 100 bar, 60 ml/min). Peak 1 was further purified by
SFC (AD-H (2.times.15 cm), 30% MeOH (0.15% DEA)/CO.sub.2, 100 bar,
60 ml/min) to afford the titled compound. LCMS (Agilent 460, 254
nm): ES (+) MS m/e=544.1 (M+1) @ 1.23 min. .sup.1H NMR (400 MHz,
DMSO-d6) .delta.: 7.72-7.85 (m, 2H), 6.92 (s, 2H), 6.81 (s, 1H),
6.57 (s, 2H), 6.54 (d, J=7.53 Hz, 1H), 4.23 (d, J=13.30 Hz, 1H),
4.15 (dd, J=3.26, 12.30 Hz, 1H), 4.08 (td, J=7.06, 10.48 Hz, 1H),
3.36-3.47 (m, 1H), 3.23-3.30 (m, 1H), 3.13 (br. s., 1H), 2.84 (t,
J=11.80 Hz, 2H), 2.57 (d, J=4.52 Hz, 3H), 2.13 (qd, J=6.17, 12.61
Hz, 1H), 1.62-1.91 (m, 4H), 1.42-1.57 (m, 1H).
##STR00060##
[0142]
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoro-
methyl)phenyl)amino)-N-methyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was separated into two peaks by
SFC (AD-H (2.times.15 cm), 50% 1:1 IPA:methanol (0.1%
DEA)/CO.sub.2, 100 bar, 60 ml/min). Peak 1 was further purified by
SFC (AD-H (2.times.15 cm), 30% MeOH (0.15% DEA)/CO.sub.2, 100 bar,
60 ml/min) to afford the titled cmpd. LCMS (Agilent 460, 254 nm):
ES (+) MS m/e=544.1 (M+1) @ 1.23 min. LCMS (Agilent 460, 254 nm):
ES (+) MS m/e=544.1 (M+1) @ 1.24 min. .sup.1H NMR (400 MHz,
DMSO-d6) .delta.: 7.80-7.89 (m, 1H), 7.72-7.80 (m, 1H), 6.97 (d,
J=6.53 Hz, 2H), 6.81 (s, 1H), 6.58 (s, 2H), 6.53 (d, J=7.78 Hz,
1H), 4.23 (d, J=13.05 Hz, 2H), 3.89-4.19 (m, 2H), 3.13 (br. s.,
1H), 2.74-3.02 (m, J=12.42, 12.42 Hz, 2H), 2.55 (d, J=4.52 Hz, 3H),
2.08 (qd, J=5.97, 12.20 Hz, 1H), 1.81 (td, J=6.24, 12.36 Hz, 3H),
1.56-1.74 (m, 1H), 1.33-1.51 (m, 1H).
Example 6
##STR00061##
[0144] Synthesis of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
A similar procedure was used as described for the synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorome-
thyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 to
afford the crude material which was purified by pre-HPLC
(MeOH/H.sub.2O with 0.05% TFA as mobile phase) to give the title
compound (45 mg, yield: 90%) as a yellow solid. ESI-MS (M+H).sup.+:
558.0. HPLC: (214 nm: 98.2%, 254 nm: 100.0%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta.: 7.77 (s, 1H), 6.92-6.89 (m, 1H), 6.83-6.81 (m,
1H), 6.79 (s, 1H), 4.38-4.38 (m, 2H), 4.05-4.00 (m, 2H), 3.55-3.53
(m, 1H), 3.45-3.40 (m, 2H), 3.15-2.89 (m, 7H), 2.21-2.16 (m, 1H),
1.90-1.86 (m, 3H), 1.66-1.56 (m, 2H).
##STR00062##
[0145]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carb-
oxamide. The title compound was obtained from chiral separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide using
a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then the resulting mixture containing a pair of isomers
was further separated into the single enantiomers using a ChiralPak
IA (2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H).sup.+: 558.0 .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 7.92
(d, J=1.76 Hz, 1H), 6.94 (s, 1H), 6.72 (d, J=7.78 Hz, 2H), 5.21 (d,
J=3.51 Hz, 1H), 4.70 (s, 2H), 4.45 (dd, J=2.76, 12.80 Hz, 2H),
4.17-4.32 (m, 1H), 3.64-3.80 (m, 2H), 3.44-3.58 (s, 3H), 3.09 (s,
3H), 3.00-3.09 (m, 1H), 2.95 (s, 3H), 2.40 (dd, J=5.52, 13.30 Hz,
1H), 1.63-1.99 (m, 3H), 1.26-1.43 (m, 1H).
##STR00063##
[0146]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carb-
oxamide. The title compound was obtained from chiral separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide using
a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then the resulting mixture containing a pair of isomers
was further separated into the single enantiomers using a ChiralPak
IA (2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H).sup.+: 558.0 .sup.1H NMR (400 MHz, (400 MHz, CDCl.sub.3)
.delta.: 7.93 (d, J=1.26 Hz, 1H), 6.93 (s, 1H), 6.69 (br. s., 2H),
5.06 (d, J=4.27 Hz, 1H), 4.71 (s, 1H), 4.45 (d, J=12.55 Hz, 2H),
4.16-4.26 (m, 1H), 3.66-3.81 (m, 2H), 3.54-3.64 (m, 1H), 3.40-3.54
(m, 2H), 3.01-3.10 (m, 4H), 2.95 (s, 3H), 2.37 (dd, J=5.27, 13.05
Hz, 1H), 1.91-2.02 (m, 2H), 1.48-1.75 (m, 2H).
##STR00064##
[0147]
(3S,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carb-
oxamide. The title compound was obtained from chiral separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide using
a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then the resulting mixture containing a pair of isomers
was further separated into the single enantiomers using a ChiralPak
IA (2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H).sup.+: 558.0 .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 7.92
(d, J=1.76 Hz, 1H), 6.94 (s, 1H), 6.72 (d, J=7.78 Hz, 2H), 5.21 (d,
J=3.51 Hz, 1H), 4.70 (s, 2H), 4.45 (dd, J=2.76, 12.80 Hz, 2H),
4.19-4.30 (m, 1H), 3.66-3.79 (m, 2H), 3.47-3.56 (m, 3H), 3.09 (s,
3H), 2.97-3.07 (m, 1H), 2.95 (s, 3H), 2.40 (dd, J=5.52, 13.30 Hz,
1H), 1.81-1.97 (m, 3H), 1.73 (dd, J=3.76, 12.80 Hz, 1H).
##STR00065##
[0148]
(3R,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carb-
oxamide. The title compound was obtained from chiral separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide using
a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then each mixture containing a pair of isomers was
further separated into the single enantiomers using a ChiralPak IA
(2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H).sup.+: 558.0 .sup.1H NMR (400 MHz, (400 MHz, CDCl.sub.3)
.delta.: 7.93 (d, J=1.26 Hz, 1H), 6.93 (s, 1H), 6.69 (br. s., 2H),
5.06 (d, J=4.27 Hz, 1H), 4.71 (s, 1H), 4.45 (d, J=12.55 Hz, 2H),
4.16-4.26 (m, 1H), 3.66-3.81 (m, 2H), 3.54-3.64 (m, 1H), 3.40-3.54
(m, 2H), 3.01-3.10 (m, 4H), 2.95 (s, 3H), 2.37 (dd, J=5.27, 13.05
Hz, 1H), 1.91-2.02 (m, 2H), 1.48-1.75 (m, 2H).
Example 7
##STR00066##
[0150] Synthesis of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)amino)-4'-(4-methylpiperazine-1-carbonyl)-[1,3'-bipiperidin]-2-one-
. A similar procedure was used as described for the synthesis of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 to
afford 23 which was purified by reverse phase HPLC (MeOH/H.sub.2O
with 0.05% NH.sub.3.H.sub.2O as mobile phase) to afford the title
compound (100 mg, yield: 70%) as a yellow solid. ESI-MS
(M+H).sup.+: 613.24. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.:
7.94 (s, 1H), 6.94 (s, 1H), 6.73-6.67 (m, 2H), 5.25-5.03 (m, 1H),
4.71 (s, 2H), 4.49-4.40 (m, 2H), 4.35-4.16 (m, 1H), 3.82-3.64 (m,
3H), 3.62-3.41 (m, 6H), 3.08-2.97 (m, 1H), 2.52-2.34 (m, 3H),
2.30-2.25 (m, 2H), 2.20 (s, 3H), 1.85-1.64 (m, 2H), 1.72-1.64 (m,
2H), 1.49-1.31 (m, 1H).
##STR00067##
[0151]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-4'-(4-methylpiperazine-1-carbonyl)-[1,3'-bipip-
eridin]-2-one. The title compound was obtained from chiral
separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 23
using a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then the resulting mixture containing a pair of isomers
was further separated into the single enantiomers using a ChiralPak
IA (2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H).sup.+: 613.2 .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.. 7.95
(s, 1H), 6.83-6.97 (m, 3H), 4.50-4.68 (m, 2H), 4.28-4.40 (m, 1H),
3.66-3.91 (m, 8H), 3.30-3.52 (m, 4H), 3.14 (t, J=12.42 Hz, 2H),
2.73 (br. s., 2H), 2.27 (dd, J=5.65, 12.93 Hz, 1H), 1.83-2.05 (m,
2H), 1.54-1.79 (m, 2H).
##STR00068##
[0152]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-4'-(4-methylpiperazine-1-carbonyl)-[1,3'-bipip-
eridin]-2-one. The title compound was obtained from chiral
separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 23
using a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then the resulting mixture containing a pair of isomers
was further separated into the single enantiomers using a ChiralPak
IA (2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H).sup.+: 613.2. H NMR (400 MHz, CD.sub.3OD) .delta.. 7.91-7.99
(m, 1H), 6.84-6.97 (m, 3H), 4.57 (dd, J=14.18, 19.70 Hz, 2H), 4.34
(br. s., 1H), 3.42-3.53 (m, 1H), 3.37 (d, J=1.51 Hz, 3H), 3.05-3.19
(m, 1H), 2.86 (t, J=7.53 Hz, 1H), 2.68-2.78 (m, 2H), 2.26 (dd,
J=5.65, 12.93 Hz, 1H), 1.82-2.03 (m, 3H), 1.55-1.79 (m, 2H).
##STR00069##
[0153]
(3S,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethyl)phenyl)amino)-4'-(4-methylpiperazine-1-carbonyl)-[1,3'-bipip-
eridin]-2-one. The title compound was obtained from chiral
separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 23
using a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then the resulting mixture containing a pair of isomers
was further separated into the single enantiomers using a ChiralPak
IA (2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. ESI-MS
(M+H): 613.2. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 7.94 (s,
1H), 6.87-6.93 (m, 3H), 4.57 (dd, J=14.18, 19.70 Hz, 1H), 4.34 (br.
s., 1H), 3.43-3.51 (m, 1H), 3.36-3.38 (m, 2H), 3.13 (t, J=12.30 Hz,
1H), 2.86 (t, J=7.53 Hz, 1H), 2.73 (br. s., 1H), 2.26 (dd, J=5.65,
12.93 Hz, 1H), 1.96-2.03 (m, 1H), 1.83-1.94 (m, 1H), 1.51-1.75 (m,
1H).
##STR00070##
[0154]
((3R,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(t-
rifluoromethyl)phenyl)amino)-4'-(4-methylpiperazine-1-carbonyl)-[1,3'-bipi-
peridin]-2-one. The title compound was obtained from chiral
separation of
trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl-
)phenyl)
amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 23
using a two step chiral SFC separation. Firstly, the mixture was
separated into two peaks containing a mixture of two diastereomers
((3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorom-
ethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
and
(3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluo-
romethyl)phenyl)amino)-N,N-dimethyl-2-oxo-[1,3'-bipiperidine]-4'-carboxami-
de) using a ChiralPak IC (2.times.15 cm, 30% methanol w/0.1 DEA)
column, and then each mixture containing a pair of isomers was
further separated into the single enantiomers using a ChiralPak IA
(2.times.15 cm, 30% methanol w/0.1% DEA 100 bar) column. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta.: 7.96 (br. s., 1H), 6.90 (br. s.,
1H), 6.76 (d, J=10.04 Hz, 2H), 4.60 (t, J=14.06 Hz, 2H), 4.19-4.32
(m, 1H), 3.67-3.78 (m, 1H), 3.43-3.54 (m, 3H), 3.35-3.38 (m, 3H),
3.16 (t, J=12.42 Hz, 1H), 2.86 (t, J=7.40 Hz, 2H), 2.79 (s, 3H),
2.32 (dd, J=5.02, 12.80 Hz, 1H), 1.89-2.07 (m, 4H), 1.62-1.76 (m,
5H), Example 8
##STR00071## ##STR00072##
[0155] The synthesis of
1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-fluoro-5-(trifluoromethyl)pheny-
l)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. A similar
procedure was used as described for the synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorome-
thyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 to
afford the crude material which was purified by pre-HPLC
(MeOH/H.sub.2O with 0.05% NH.sub.3.H.sub.2O as mobile phase) to
give the title compound (175 mg, yield: 69%) as a yellow solid.
ESI-MS (M+H).sup.+: 514.19. HPLC: (214 nm: 96.13%, 254 nm: 96.53%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 7.79-7.78 (m, 1H), 6.76
(s, 1H), 6.63-6.54 (m, 2H), 4.41-4.36 (m, 2H), 4.08-4.06 (m, 1H),
3.55-3.41 (m, 3H), 3.28-3.25 (m, 1H), 2.99-2.93 (m, 1H), 2.28-2.21
(m, 1H), 1.98-1.78 (m, 6H).
##STR00073##
[0156]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-fluoro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was separated into three peaks by
SFC (IA (3.times.15 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70
ml/min) and peak 3 corresponded to the titled compound. LCMS
(Agilent 460, 254 nm): ES (+) MS m/e=514.0 (M+1) @ 1.09 min.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 7.91 (br. s., 1H), 6.66
(d, J=8.53 Hz, 1H), 6.63 (s, 1H), 6.46 (d, J=10.79 Hz, 1H), 6.12
(br. s., 1H), 5.47 (br. s., 1H), 5.16 (d, J=3.51 Hz, 1H), 4.91 (br.
s., 2H), 4.35-4.54 (m, 2H), 3.82 (td, J=5.11, 10.60 Hz, 2H),
3.51-3.60 (m, 1H), 3.34-3.48 (m, 3H), 2.96 (t, J=12.30 Hz, 1H),
2.35-2.47 (m, 1H), 1.91-2.06 (m, 3H), 1.84 (dq, J=3.89, 12.76 Hz,
1H), 1.48-1.62 (m, 1H).
##STR00074##
[0157]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-fluoro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was separated into three peaks by
SFC (IA (3.times.15 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70
ml/min). Peak 2 of 3 corresponded to desired compound. LCMS
(Agilent 460, 254 nm): ES (+) MS m/e=514.0 (M+1) @ 1.10 min.
.sup.1H NMR (400 MHz, DMSO-d6) .delta.: 7.77 (d, J=1.76 Hz, 1H),
7.39 (s, 1H), 6.85 (s, 1H), 6.81 (s, 1H), 6.74 (d, J=12.30 Hz, 1H),
6.47-6.66 (m, 4H), 4.23 (d, J=12.80 Hz, 2H), 3.90-4.18 (m, 2H),
3.34-3.46 (m, 2H), 3.12 (br. s., 1H), 2.94 (br. s., 1H), 2.82 (t,
J=12.42 Hz, 1H), 2.10 (qd, J=5.75, 12.11 Hz, 1H), 1.74-1.92 (m,
3H), 1.56-1.72 (m, 1H), 1.37-1.52 (m, 1H).
##STR00075##
[0158]
(3R,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-fluoro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was separated into three peaks by
SFC (IA (3.times.15 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70
ml/min). Peak 1 of 3 was further purified by SFC (IA (3.times.15
cm), 30% iPrOH (0.1% DEA)/CO.sub.2, 100 bar, 70 ml/min) to afford
the titled compound. LCMS (Agilent 460, 254 nm): ES (+) MS
m/e=514.0 (M+1) @ 1.10 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta.:
7.77 (d, 1.5 Hz, 1H), 7.39 (s., 1H), 6.85 (s, 1H), 6.81 (s., 1H),
6.74 (d, J=12.30 Hz, 1H), 6.47-6.66 (m, 4H), 4.16-4.46 (m, 2H),
3.95-4.16 (m, 2H), 3.34-3.48 (m, 2H), 3.12 (br. s., 1H), 2.87-3.01
(m, 2H), 2.82 (t, J=12.30 Hz, 1H), 2.10 (qd, J=5.75, 12.11 Hz, 1H),
1.74-1.92 (m, 3H), 1.54-1.74 (m, 1H), 1.35-1.52 (m, 1H).
##STR00076##
[0159]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-fluoro-5-(tr-
ifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was separated into three peaks by
SFC (IA (3.times.15 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70
ml/min). Peak 1 of 3 was further purified by SFC (IA (3.times.15
cm), 30% iPrOH (0.1% DEA)/CO.sub.2, 100 bar, 70 ml/min) to afford
the titled compound. LCMS (Agilent 460, 254 nm): ES (+) MS
m/e=514.0 (M+1) @ 1.10 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta..
7.77 (d, J=1.76 Hz, 1H), 7.38 (br. s., 1H), 6.84 (s, 2H), 6.70 (d,
J=12.30 Hz, 1H), 6.47-6.65 (m, 4H), 4.18-4.48 (m, 2H), 3.92-4.18
(m, 2H), 3.38-3.49 (m, 1H), 3.20-3.30 (m, 1H), 3.11 (br. s., 1H),
2.88-2.99 (m, 1H), 2.83 (t, J=12.30 Hz, 1H), 2.14 (qd, J=6.03,
12.52 Hz, 1H), 1.74-1.92 (m, 3H), 1.59-1.74 (m, 1H), 1.41-1.58 (m,
1H).
Example 9
##STR00077## ##STR00078##
[0161] The synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-fluorophenyl-
) amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. A similar
procedure was used as described for the synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorome-
thyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 to
afford the crude material which was purified by pre-HPLC
(MeOH/H.sub.2O with 0.05% NH.sub.3.H.sub.2O as mobile phase) to
give the title compound (141 mg, Y: 30%) as a white solid. ESI-MS
(M+H).sup.+: 479.9. HPLC: (214 nm: 100%, 254 nm: 100%). .sup.1H NMR
(400 MHz, DMSO d6) .delta.: 7.78-7.77 (m, 1H), 7.40-7.38 (m, 1H),
6.86-6.82 (m, 1H), 6.62-6.55 (m, 3H), 6.45-6.37 (m, 3H), 4.26-3.94
(m, 4H), 3.47-3.39 (m, 1H), 3.20-3.03 (m, 2H), 2.90-2.78 (m, 2H),
2.18-2.04 (m, 1H), 1.86-1.34 (m, 5H).
##STR00079##
[0162]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-flu-
orophenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. The
mixture of four diastereomers was separated into three peaks by SFC
(IC (2.times.15 cm), 25% MeOH (0.1% DEA)/CO.sub.2, 100 bar, 60
ml/min) to afford the title compound as peak 3 respectively. LCMS
(Agilent 460, 254 nm): ES (+) MS m/e=480.0 (M+1) @ 1.01 min.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta.: 7.90 (br. s., 1H), 6.44
(d, J=8.53 Hz, 1H), 6.40 (s, 1H), 6.30 (br. s., 1H), 6.23 (d,
J=11.04 Hz, 1H), 5.63 (br. s., 1H), 5.09 (br. s., 1H), 4.94 (br.
s., 2H), 4.45 (d, J=12.80 Hz, 2H), 3.68-3.95 (m, 2H), 3.49-3.56 (m,
2H), 3.35-3.46 (m, 2H), 2.89-2.99 (m, 1H), 2.31-2.44 (m, 1H),
1.90-2.04 (m, 3H), 1.76-1.89 (m, 1H), 1.49-1.61 (m, 1H).
##STR00080##
[0163]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-flu-
orophenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. The
mixture of four diastereomers was separated into three peaks by SFC
(IC (2.times.15 cm), 25% MeOH (0.1% DEA)/CO.sub.2, 100 bar, 60
ml/min) to afford the title compound as peak 1 respectively. LCMS
(Agilent 460, 254 nm): ES (+) MS m/e=480.0 (M+1) @ 1.01 min.
.sup.1H NMR (400 MHz, DMSO-d6) .delta.: 7.77 (d, J=1.76 Hz, 1H),
7.39 (s., 1H), 6.81 (s, 1H), 6.57 (s, 3H), 6.46 (d, J=12.30 Hz,
1H), 6.39 (dd, J=1.76, 8.78 Hz, 1H), 6.34 (d, J=7.53 Hz, 1H), 4.28
(br. s., 1H), 4.23 (d, J=13.05 Hz, 1H), 4.13 (dd, J=2.76, 12.30 Hz,
1H), 4.03 (td, J=6.56, 10.98 Hz, 1H), 3.33-3.46 (m, 2H), 3.11 (br.
s., 1H), 2.94 (br. s., 1H), 2.82 (t, J=12.30 Hz, 1H), 2.09 (qd,
J=5.75, 12.11 Hz, 1H), 1.72-1.92 (m, 3H), 1.56-1.72 (m, 1H),
1.29-1.50 (m, 1H).
##STR00081##
[0164]
(3S,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-flu-
orophenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. The
mixture of four diastereomers was separated into three peaks by SFC
(IC (2.times.15 cm), 25% MeOH (0.1% DEA)/CO.sub.2, 100 bar, 60
ml/min). Peak 2 of 3 was further purified by SFC (IA (3.times.15
cm), 30% iPrOH (0.1% DEA)/CO.sub.2, 100 bar, 60 ml/min) to afford
the title compound. LCMS (Agilent460, 254 nm): ES (+) MS m/e=480.0
(M+1) @ 1.01 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta.: 7.77 (d,
J=2.01 Hz, 1H), 7.37 (br. s., 1H), 6.84 (s, 1H), 6.57 (s, 2H), 6.55
(br. s., 1H), 6.30-6.48 (m, 3H), 4.28 (br. s., 1H), 4.23 (d,
J=13.05 Hz, 1H), 4.13 (dd, J=3.39, 12.67 Hz, 1H), 3.97 (td, J=6.84,
10.42 Hz, 1H), 3.38-3.50 (m, 1H), 3.22-3.29 (m, 1H), 3.10 (br. s.,
1H), 2.71-2.97 (m, 1H), 2.83 (t, J=12.30 Hz, 1H), 2.13 (qd, J=6.13,
12.49 Hz, 1H), 1.73-1.91 (m, 3H), 1.58-1.73 (m, 1H), 1.39-1.53 (m,
1H).
##STR00082##
[0165]
(3R,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-flu-
orophenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. The
mixture of four diastereomers was separated into three peaks by SFC
(IC (2.times.15 cm), 25% MeOH (0.1% DEA)/CO.sub.2, 100 bar, 60
ml/min). Peak 2 of 3 was further purified by SFC (IA (3.times.15
cm), 30% iPrOH (0.1% DEA)/CO.sub.2, 100 bar, 60 ml/min) to afford
the title compound. LCMS (Agilent460, 254 nm): ES (+) MS m/e=480.0
(M+1) @ 1.01 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.77 (d,
J=1.76 Hz, 1H), 7.39 (s, 1H), 6.81 (s, 1H), 6.57 (s, 3H), 6.46 (td,
J=2.01, 12.30 Hz, 1H), 6.39 (td, J=1.95, 8.66 Hz, 1H), 6.34 (d,
J=7.53 Hz, 1H), 4.18-4.48 (m, 2H), 4.09-4.18 (m, 1H), 3.79-4.09 (m,
1H), 3.33-3.45 (m, 2H), 3.11 (br. s., 1H), 2.92 (br. s., 1H), 2.82
(t, J=12.42 Hz, 1H), 2.09 (qd, J=5.75, 12.11 Hz, 1H), 1.74-1.93 (m,
3H), 1.51-1.74 (m, 1H), 1.32-1.51 (m, 1H).
Example 10
##STR00083## ##STR00084##
[0167] The synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorome-
thoxy) phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide. A
similar procedure was used as described for the synthesis of
(3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluorome-
thyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 14 to
afford the crude material which was purified by pre-HPLC
(MeOH/H.sub.2O with 0.05% NH.sub.3.H.sub.2O as mobile phase) to
give the title compound (320 mg, yield: 44%) as a yellow solid.
ESI-MS (M+H).sup.+: 546.16. HPLC: (214 nm: 98.4%, 254 nm: 98.0%).
.sup.1H NMR (400 MHz, DMSO-d6) .delta.: 7.77 (s, 1H), 7.39 (s, 1H),
6.84-6.81 (m, 1H), 6.75-6.72 (m, 1H), 6.62-6.57 (m, 3H), 6.52-6.47
(m, 2H), 4.24-3.98 (m, 4H), 3.47-3.40 (m, 1H), 3.17-2.99 (m, 2H),
2.86-2.79 (m, 2H), 2.15-1.99 (m, 1H), 1.86-1.60 (m, 4H), 1.48-1.39
(m, 1H).
##STR00085##
[0168]
(3R,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethoxy)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was purified by SFC (AD-H
(2.times.25 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70 ml/min)
to afford the title compound. LCMS (Agilent460, 254 nm): ES (+) MS
m/e=546.0 (M+1) @ 1.20 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta.:
7.77 (d, J=1.76 Hz, 1H), 7.39 (br. s., 1H), 6.81 (s, 1H), 6.75 (s,
1H), 6.62 (s, 1H), 6.57 (s, 2H), 6.38-6.52 (m, 2H), 4.23 (d,
J=13.05 Hz, 2H), 3.92-4.18 (m, 2H), 3.34-3.45 (m, 2H), 3.11 (br.
s., 1H), 2.93 (br. s., 1H), 2.82 (t, J=12.30 Hz, 1H), 2.08 (qd,
J=5.75, 12.11 Hz, 1H), 1.74-1.92 (m, 3H), 1.56-1.73 (m, 1H),
1.36-1.50 (m, 1H).
##STR00086##
[0169]
(3S,3'S,4'R)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethoxy)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was purified by SFC (AD-H
(2.times.25 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70 ml/min)
to afford the title compound. LCMS (Agilent 460, 254 nm): ES (+) MS
m/e=546.0 (M+1) @ 1.23 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta.:
7.77 (d, J=2.01 Hz, 1H), 7.37 (br. s., 1H), 6.84 (s, 1H), 6.72 (s,
1H), 6.60 (s, 1H), 6.57 (s, 2H), 6.43-6.54 (m, 2H), 4.23 (d,
J=13.05 Hz, 1H), 4.22 (br. s., 1H), 4.13 (dd, J=3.26, 12.30 Hz,
1H), 4.01 (td, J=6.81, 10.23 Hz, 1H), 3.44 (td, J=6.18, 12.49 Hz,
1H), 3.20-3.29 (m, 1H), 3.11 (br. s., 1H), 2.88 (br. s., 1H), 2.83
(t, J=12.30 Hz, 1H), 2.12 (qd, J=6.05, 12.46 Hz, 1H), 1.73-1.91 (m,
3H), 1.59-1.73 (m, 1H), 1.48 (td, J=9.41, 19.33 Hz, 1H).
##STR00087##
[0170]
(3S,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethoxy)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was purified by SFC (AD-H
(2.times.25 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70 ml/min)
to afford the title compound. LCMS (Agilent 460, 254 nm): ES (+) MS
m/e=546.0 (M+1) @ 1.22 min. .sup.1H NMR (400 MHz, DMSO-d6) .delta.:
7.77 (d, J=2.01 Hz, 1H), 7.38 (br. s., 1H), 6.81 (s, 1H), 6.75 (s,
1H), 6.62 (s, 1H), 6.57 (s, 2H), 6.42-6.51 (m, 2H), 4.23 (d,
J=12.80 Hz, 2H), 3.97-4.18 (m, 2H), 3.34-3.44 (m, 2H), 3.10 (br.
s., 1H), 2.93 (br. s., 1H), 2.82 (t, J=12.17 Hz, 1H), 2.03-2.15 (m,
1H), 1.77-1.90 (m, 3H), 1.57-1.73 (m, 1H), 1.37-1.48 (m, 1H).
##STR00088##
[0171]
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(tr-
ifluoromethoxy)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide.
The mixture of four diastereomers was purified by SFC (AD-H
(2.times.25 cm), 30% EtOH (0.1% DEA)/CO.sub.2, 100 bar, 70 ml/min)
to afford the titled compound. LCMS (Agilent 460, 254 nm): ES (+)
MS m/e=546.0 (M+1) @ 1.23 min. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta.: 7.93 (s, 1H), 6.60 (s, 1H), 6.52 (s, 1H), 6.35 (s, 1H),
5.85 (br. s., 1H), 5.32 (br. s., 1H), 4.97-5.15 (m, 1H), 4.78 (br.
s., 2H), 4.46 (d, J=13.05 Hz, 2H), 3.67-3.87 (m, 2H), 3.34-3.60 (m,
4H), 2.99 (t, J=12.17 Hz, 1H), 2.34-2.49 (m, 1H), 1.91-2.08 (m,
3H), 1.83 (dq, J=3.76, 12.72 Hz, 1H), 1.47-1.74 (m, 1H).
Example 11
[0172] In vitro BTK kinase assay: BTK-POLYGAT-LS ASSAY. The purpose
of the BTK in vitro assay was to determine compound potency against
BTK through the measurement of IC.sub.50. Compound inhibition was
measured after monitoring the amount of phosphorylation of a
fluorescein-labeled polyGAT peptide (Invitrogen PV3611) in the
presence of active BTK enzyme (Upstate 14-552), ATP, and inhibitor.
The BTK kinase reaction was done in a black 96 well plate (costar
3694). For a typical assay, a 24 uL aliquot of an ATP/peptide
master mix (final concentration; ATP 10 uM, polyGAT 100 nM) in
kinase buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl.sub.2, 200 uM
Na.sub.3PO.sub.4, 5 mM DTT, 0.01% Triton X-100, and 0.2 mg/ml
casein) was added to each well. Next, 1 uL of a 4-fold, 40.times.
compound titration in 100% DMSO solvent was added, followed by
adding 15 uL of BTK enzyme mix in 1.times. kinase buffer (with a
final concentration of 0.25 nM). The assay was incubated for 30
minutes before being stopped with 28 uL of a 50 mM EDTA solution.
Aliquots (5 uL) of the kinase reaction were transferred to a low
volume white 384 well plate (Corning 3674), and 5 uL of a 2.times.
detection buffer (Invitrogen PV3574, with 4 nM Tb-PY20 antibody,
Invitrogen PV3552) was added. The plate was covered and incubated
for 45 minutes at room temperature. Time resolved fluorescence
(TRF) on Molecular Devices M5 (332 nm excitation; 488 nm emission;
518 nm fluorescein emission) was measured. IC.sub.50 values were
calculated using a four parameter fit with 100% enzyme activity
determined from the DMSO control and 0% activity from the EDTA
control.
[0173] Selected compounds of formula I were tested and found to be
active in the polyGAT assay. Compounds I-1, I-2, I-3, I-4, I-5 and
I-7 gave IC.sub.50 values of 0.73 nM, 0.68 nM, 2.07 nM, 0.63 nM,
1.6 nM, and 1.2 nM respectively. Compound I-6 has an IC.sub.50
value less than 1 nM. Comparator compound I.sup.C, shown below,
produced an IC.sub.50 value of 2.0 nM.
##STR00089##
Example 12
Study Protocol to Determine Activation of the PXR Nuclear Receptor
in Human DPX2 Cells
[0174] a) Protocol Summary: PXR has been shown to be a primary
nuclear receptor that mediates drug-induced expression of CYP3A4
(Bertilsson G, et al.; Proc Natl Acad Sci USA. 1998 Oct. 13;
95(21):12208-13). Based on this pathway of CYP3A4 induction,
cell-based PXR reporter gene assay is commonly used to screen new
molecular entities (NMEs) in early drug discovery stage, for their
potential to induce CYP3A4 (Luo G, et al.; Drug Metab Dispos. 2002
July; 30(7):795-804.) Studies were designed to evaluate the effect
of new molecular entities (NMEs) on the activation of human PXR in
DPX2 cells. Cell lines stably transfected with the PXR nuclear
receptor and corresponding response elements were seeded into
96-well plates. Twenty-four hr after seeding, cells were treated
with 6 distinct concentrations of NMEs in triplicate wells (see
below), and cells then returned to the incubator for an additional
24 hr. At the end of this incubation period, the number of viable
cells/well were determined using Promega's Cell Titer Fluor
cytotoxicity assay. Following this assay, Promega's ONE-Glo was
added to the same wells and reporter gene activity assessed.
[0175] b) Test System: The test system consisted of the stably
transformed DPX2 tumor cell line plated on 96-well microtiter
plates. An expression vector harboring the PXR nuclear receptor
plus the appropriate enhancers and promoters linked to the
luciferase reporter gene have been stably integrated into these
tumor cell lines. Receptor activation was assessed by monitoring
reporter gene activity, and by comparing the results to
vehicle-treated cells. Positive controls consist of cells treated
with 6 different concentrations (0.1, 0.5, 1, 5, 10, and 20 .mu.M)
of rifampicin. In this manner, compounds activating PXR can be
easily and rapidly identified. Since stably-integrated cell lines
were used, it is possible to observe from 3- to 70-fold receptor
activation.
[0176] c) Data Processing and Receptor Activation Kinetics: Data
processed using MS-Excel was calculated as the mean (n=3) and % CV
of the fold PXR activation relative to vehicle-treated cells at
each of the 6 different doses. All activation data was normalized
to the number of viable cells/well. Results were also expressed as
a percentage of the response given by the appropriate positive
control at a 10 M dose. EC.sub.50 and E.sub.max values were derived
for test compounds that give receptor activation using nonlinear
regression of typical log dose-response curves (Prism V5.0c,
GraphPad Software, San Diego, Calif.). Agents exhibiting atypical
dose-response curves were not analyzed in this fashion.
[0177] d) New Molecular Entities (NMEs): Test compounds were tested
at 0.05, 0.1, 0.5, 1, 2.5, and 10 .mu.M
[0178] Selected compounds of formula I were tested in the PXR
assay. Compounds I-1, I-2, I-3, I-4, and I-5 gave PXR % induction
(relative to 10 uM rifampin) of 62%, 42%, 47%, 67%, and 90%,
respectively. Comparator compound I.sup.C, shown above, produced a
PXR % induction of 95%.
Example 13
Protocol for FastPatch hERG Inhibition Assay
[0179] The cardiac potassium channel, hERG, is responsible for a
rapid delayed rectifier current (I.sub.Kr) in human ventricle and
inhibition of I.sub.Kr is the most common cause of cardiac action
potential prolongation by non-cardiac drugs (see, e.g., Weirich and
Antoni, Basic Res. Cardiol., 93, Suppl. 1, 125-32, 1998; Yap and
Camm, Clin. Exp. Allergy, 29, Suppl. 3, 174-81, 1999). Increased
action potential duration has been cited as a factor in causing
prolongation of the QT interval that has been associated with a
dangerous ventricular arrhythmia, torsade de pointes (Brown and
Rampe, Pharmaceutical News, 7, 15-20, 2000).
[0180] The in vitro effects of provided compounds was investigated
on the hERG (human ether-a-go-go-related gene) potassium channel
current (a surrogate for I.sub.Kr, the rapidly activating, delayed
rectifier cardiac potassium current) expressed in human embryonic
kidney (HEK293) cells stably transfected with hERG cDNA. Cells were
placed in HEPES-buffered physiological saline solution in a
glass-lined 96-well plate and loaded with appropriate amounts of
test and control solutions for a duration of a 3-minute exposure at
each concentration. Test compound was diluted in 0.3% DMSO. An
automated parallel patch clamp system, QPatch HT (Sophion
Bioscience A/S, Denmark), was used to evaluate at various
concentrations (e.g., 10 .mu.M). The IC.sub.50 values was estimated
based on the hERG inhibition data. The study was performed at
ChanTest (14656 Neo Parkway, Cleveland, Ohio). The QPatch screen is
further described by Janzen and Bernasconi (eds.), High Throughput
Screening, Methods and Protocols, Second Edition, vol. 565, chapter
10, pg. 209-223, 2009.
[0181] Selected compounds of formula I were tested in the hERG
assay. Compounds I-1, I-2, I-3, and I-4 gave hERG IC.sub.50 of 15.6
uM, 30 uM, 14.6 uM, and 13.7 uM, respectively. Compound I-5 shows
no observable activity in the hERG assay at 10 uM (no IC.sub.50
available). Compound I-6 shows little observable hERG activity
(<20% inhibition) at 10 uM (no IC.sub.50 available). Compound
I-7 shows hERG activity (65% inhibition) at 10 uM (no IC.sub.50
available). Comparator compound I.sup.C, shown above, produced a
hERG IC.sub.50 of 1.18 uM or activity (87% inhibition) at 10
uM.
Example 14
GSH Trapping in Human Liver Microsome:Protocol
[0182] Test compound (final concentration 10 uM) is incubated with
either human or rat liver microsomes (final concentration 1 mg/mL),
along with activating cofactors NADPH (final concentration 1 mM),
potassium phosphate (final concentration 100 mM pH 7.4), magnesium
chloride (final concentration 3.3 mM) and the trapping agent GSH
(final concentration 5 mM). The incubation mixture is incubated for
60 min at 37.degree. C. and terminated with ice cold acetonitrile
(equal volume as incubation mixture) and the supernatents isolated.
The supernatants are either injected directly for LC/MS/MS analysis
or dried under N.sub.2 and reconstituted in water:acetonitrile
(80:20) mixture before LC/MS/MS analysis. The corresponding GSH
conjugate is evaluated via LC/MS/MS, using a Triple TOF5600/Xevo
Qtof MSe.
Example 15
Rat Collagen-Induced Arthritis Model
[0183] The collagen induced arthritis (CIA) model in female Lewis
rats requires primary T and B cell immune responses to type II
collagen (CII) immunization for the development of a severe
inflammatory disease (see Goldschmidt T J, Holmdahl R. Cell
Immunol. 154(1):240-8, 1994; Helfgott, S. M., et al; Clin. Immunol.
Immunopathol. 31:403, 1984; Holmdahl R. et al., J Autoimmun.
7(6):739-52, 1994; and Stuart, J. M., et al., J. Exp. Med. 155:1,
1982). Clinical disease onsets after a secondary CII challenge and
the disease progresses over the following eight days.
[0184] Generally, female Lewis rats are immunized with bovine
collagen type II in incomplete Freund's adjuvant. Rats (N=10/group)
receive daily oral administration of test compound or vehicle BID
by oral gavage beginning on day 1 (therapeutic). Clinical severity
of arthritis is assessed by caliper measurements of ankles taken
every day beginning on Day 0.
[0185] Detailed protocol: Female Lewis rats are immunized
subcutaneously with bovine collagen type II (1:1 emulsion of 2
mg/ml bovine CII in 0.01 N acetic acid: Incomplete Freund's
Adjuvant) at three sites of back skin. Six days post immunization
rats receive a second subcutaneous injection of bovine CII. A
compound of formula I suspension or vehicle (0.5% CMC, 0.1% Tween
80) is administered by oral gavage BID beginning on day 0
(prophylactic) (n=10 animals/group). Clinical severity of CIA is
assessed by caliper measurements of ankles taken every day
beginning on Day 9. Baseline ankle caliper measurements are taken
and confirmed as clinically normal (0.260-0.264 in) for
prophylactic treatment. Baseline ankle caliper measurements for
established disease animals is assessed on day 1 of therapeutic
dosing and animals are randomly assigned to treatment groups after
confirmation of clinical disease onset (0.2751-0.2755 in). Data are
analyzed across all groups using a one-way analysis of variance
(1-way ANOVA), along with an appropriate multiple comparison
post-test. Significance for all tests is set at p<0.05.
Example 16
Analysis of BCR Pathway Activation Via Inhibition of
Phosphorylation of PLC.gamma.2
[0186] Protocol: One day before treatment, Ramos cells are plated
at a density of 3.times.10.sup.5 cells per well in 200 .mu.L of
complete medium in a 96-well tissue culture filter plates
(Millipore, Billerica, Mass.). On the day of treatment, used medium
is removed by filtration and the cells re-suspended in 200 .mu.L
serum free medium containing serial compound dilutions and DMSO to
0.1%, then incubated for 2 hours at 37.degree. C. Cells are
stimulated for 5 minutes with 10 .mu.g/mL goat anti-human IgM at
37.degree. C. All medium is removed by filtration and the cells are
rinsed with ice cold PBS then lysed on ice for 1 hour with lysis
buffer containing; 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1
mM EGTA, 2 mM Na.sub.3VO.sub.4, 1% Triton X-100, 0.1% SDS, protease
inhibitor cocktail, 1 mM phenylmethylsulfonyl fluoride, (PMSF),
Phosphatase inhibitor mix 2 (Sigma cat #P5726 from Sigma, St.
Louis, Mo.), and Phosphatase inhibitor mix 3 (Sigma cat #P0044 from
Sigma, St. Louis, Mo.). Lysates are subsequently transferred to
standard MSD plates (Meso Scale Discovery, (MSD), (Gaithersburg,
Md.)), pretreated with capture antibody (anti-total PLC.gamma.2
antibody B10, (SantaCruz Biotechnologies (Santa Cruz, Calif.)) and
blocked with BSA according to the manufacturer's directions.
Lysates are incubated in the prepared MSD plates overnight at
4.degree. C. with gentle agitation. Wells are washed three times
with TBST and treated with anti pPLC.gamma.2 (SantaCruz) in 1% BSA
in PBS for 1 hour at room temperature. Wells are again washed three
times with TBST and treated with anti-rabbit sulfo-tag antibody
(MSD), for 1 hour at room temperature. After washing with TBST, MSD
read buffer is added and the luminescence is measured in an MSD
SECTOR Imager 6000. Maximum response is determined as the average
luminescence in wells containing stimulated cells treated with
anti-IgM and DMSO. Minimal response is determined as the average
luminescence in wells containing unstimulated cells treated with
DMSO alone. The maximal and minimal values are used to normalize
luminescence in compound treatment wells. The normalized values are
plotted against compound concentration on a log scale then analyzed
using Prizm software (GraphPad Software, Inc.). A sigmoidal
dose-response equation with variable slope is used to fit the data
and generate 50% inhibition concentration (IC.sub.50).
[0187] Ramos cells are incubated in 96 well plates with a range of
concentrations of a compound of formula I for 2 hours, stimulated
with 10 .mu.g/mL anti-IgM for 5 minutes, and PLC.gamma.2
phosphorylation measured using an electrochemical-luminescent
immunoassay. The EC.sub.50 is calculated using GraphPad Prism
software.
Example 17
Inhibition BCR-Induced Human B Cell Proliferation
[0188] Human CD19+ B cells are stimulated with an anti-IgM antibody
and the activity of a compound of formula I is evaluated in terms
of altering cellular metabolism after 72 hours. In this context,
cellular metabolism directly correlates with cellular activation
and proliferation, and can also reflect relative cell survival
during proliferation. Anti-IgM antibody is evaluated for effects on
B cell proliferation and determined to exhibit a half-maximal
concentration for activation of 10 .mu.g/ml. Using these activation
conditions, varying concentrations of test compound are assayed, in
triplicate in 0.1% DMSO, for impact on cellular metabolism of CD19+
B cells isolated from different donors.
[0189] Protocol: Human B cells are isolated from peripheral blood
mononuclear cells or unpurified buffy coats using Ficoll-Hypaque
gradients (Amersham) and negatively selected by magnetic cell
sorting (Human B Cell Isolation Kit II, Miltenyi Biotec). Target
cell purity is determined by flow cytometry by staining for markers
of B cells, T cells and monocytes (CD19, CD3, CD14, respectively;
BD Biosciences). Data are collected on a FACsCaliber flow cytometer
and analyzed using FloJo software (BD Biosciences). Purity of human
B cell preparations is routinely greater than 95%. Negatively
selected human B cells are stimulated with 10 g/mL anti-IgM
F(ab').sub.2 (Jackson ImmunoResearch) in 96 well plates. 100,000 B
cells in 0.2 mL RPMI+10% FBS are treated with varying
concentrations (titrated from 5000 nM to 0 nM in 0.5% DMSO) of a
compound of formula I in triplicate wells or vehicle control in
0.5% DMSO final concentration for 30 minutes at 37.degree. C., 5%
CO.sub.2, then cells are stimulated with 10 pg/mL anti-IgM
F(ab').sub.2. B cells are stimulated for 72 hr at 37.degree. C., 5%
CO.sub.2. Proliferation is measured using the CellTiter-Glo reagent
(Promega), as measured on a luminometer. Mean values are plotted
against maximum proliferation and IC.sub.50 values are determined
using GraphPad Prism v5 software.
Example 18
Evaluation of the Effect of Compounds on Myeloid Cell Activation In
Vitro
[0190] Fc.gamma.R activation of primary human macrophages.
Autoantibody and immune-complex mediated activation through
Fc.gamma.R can be modeled by activation of macrophages with
immobilized IgG. Primary human macrophages derived from GM-CSF
treated monocytes up-regulate activation markers such as CD80,
CD86, MHC antigens and the Fc.gamma.RIII receptor. Human monocyte
derived macrophages can be activated by plate-bound purified human
IgG. This stimulation crosslinks the Fc.gamma.RIII receptor and
induces the secretion of pro-inflammatory cytokines such as
TNF.alpha., IL-6, IL1.beta. and MCP-1. Compound of formula I are
evaluated for inhibition of cytokine expression following FcR
activation of human macrophages.
[0191] Generally, macrophages are cultured in plates previously
incubated with purified IgG then washed. Titrations of test
compound (10,000 nM to 0 nM) are added to these cultures. Cell
culture supernatants are analyzed by ELISA for the expression of
TNF.alpha. and IL-6.
[0192] Protocol: Human monocytes are isolated from buffy coats of
healthy donors and negatively selected by magnetic cell sorting
(Monocyte Isolation Kit II, Miltenyi Biotec). Purified monocytes
are cultured in standard media supplemented with low-IgG FBS and
100 ng/mL GM-CSF for 5-7 days to induce macrophage differentiation.
Cultured macrophages are stimulated with 100 .mu.g/mL plate-bound
purified IgG a titration of test compound (10 M to 0 nM).
Supernatants are collected after 4 hrs and 18 hrs and analyzed for
TNF.alpha. and IL-6, respectively.
Example 19
Efficacy in Mouse Collagen Antibody-Induced Arthritis
[0193] This Example relates not only to arthritis, but also
evaluates the activity of autoantibodies and immune complexes in
vivo and therefore is relevant to other inflammatory disorders such
as SLE. In this experiment, the activity of autoantibodies and
immune complexes produce a pathological endpoint that is dependent
on FcR signalling, and the Fc portion of such antibodies is
inhibited by administration of a compound of formula I.
[0194] The collagen antibody-induced arthritis (CAIA) model in
female DBA/1 mice does not require cognate T and B cell responses
for the induction of inflammation but rather relies on immune
effector mechanisms for the development of clinical disease. A
cocktail of four anti-collagen II (CII) specific monoclonal
antibodies and immune stimulatory lipopolysaccharide (LPS)
administered 3 days after CII specific antibody transfer promote
antibody-Fc-Receptor engagement (Kagari T. et al.; J Immunol.
170:4318-24 (2003)), immune complex formation, complement
activation (Banda N K, et al.; Clin Exp Immunol. 159:100-8 (2010))
and pro-inflammatory cytokine production to induce a severe
inflammatory disease over a 10 day period.
[0195] Generally, arthritis is induced by injection of a cocktail
of monoclonal anti-collagen antibodies into DBA/1 mice on day 0.
Mice (N=10/group) receive daily oral administration of test
compound either QD or BID as indicated beginning on day 0. Paw
inflammation is evaluated daily.
[0196] Protocol: Female DBA/1 mice 6-8 weeks of age receive 2 mg of
an arthitogenic four clone monoclonal antibody cocktail (Chondrex
#10100) i.v. on day 0 followed by a 50 ug dose of LPS on 3 days
later. Test compound suspension or vehicle (0.5% CMC, 0.1% Tween
80) is administered BID by oral gavage beginning on day 0 (10
animals/group) just prior to i.v. transfer of antibody cocktail.
Clinical severity of CIA is assessed by monitoring inflammation on
all four paws, applying a scale ranging from 0 to 4. Each paw is
graded as follows: 0, normal; 1, mild but definite redness and
swelling of the ankle or wrist, or redness and swelling of any
severity for 1 or 2 digits; 2, moderate to severe redness and
swelling of the ankle or wrist, or more than two digits; 3, redness
and swelling (pronounced edema) of the entire paw; and 4, maximally
inflamed limb with involvement of multiple joints. The sum of the
four individual scores is the arthritis index, with a maximal
possible score of 16 for each animal.
* * * * *